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ABSTRACT
RANTES (regulated on activation, normal T cell expressed and secreted) is a potent 
chemoattractant for T lymphocytes, but the signalling pathways utilised by RANTES 
and the other functional effects of RANTES on T lymphocytes have not been clearly 
defined. RANTES produced a "beU-shape-like" chemotactic response and a 
corresponding increase in polarisation and actin polymerisation of the human primary 
T lymphocytes.
In T lymphocytes loaded with fura-2 acetoxymethyl, the CD3 mAb, UCHT1, but not 
RANTES, elicited elevation of intracellular calcium levels. UCHT1 stimulation of T 
lymphocytes induced phosphatidic acid production and the breakdown of 
phosphatidylinositol (Ptdlns) 4,5-bisphosphate but RANTES had no effect. 
Immunoprecipitates of PI 3-kinase, derived from T lymphocytes stimulated with 
RANTES, contained increased in vitro PI 3-kinase activity compared with that present 
in immunoprecipitates from vehicle-treated cells. In addition, wortmannin, a potent PI 
3-kinase inhibitor, inhibited RANTES-induced T lymphocyte migration, polarisation, 
actin polymerisation and increased PI 3-kinase activity. Costimulation of T 
lymphocytes by UCHT1 and Chinese hamster ovary cells expressing B7 (CHO-B7+) 
induced RANTES peptide production. Also, when RANTES was used in addition to 
costimulation, it induced T lymphocyte proliferation and IL-2 receptor upregulation and 
above the levels seen with costimulation alone, but did not alter IL-2 production.
These results indicate that RANTES not only induces migration of T lymphocytes but 
plays a role in costimulation of T lymphocytes. In addition, RANTES induced 
migration of T lymphocytes is independent of detectable elevation but involves the PI 
3-kinase signalling pathway.
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Immune responses are dependent upon the immune system being able to recognise 
antigens on potential pathogens and then developing an appropriate reaction to eliminate 
the source of the antigen. Therefore, there are two main phases to a immune response: 
recognition of the antigen, which is performed by lymphocytes and the effector phase 
which involves many cells such as neutrophils, eosinophils, basophils, mast cells and 
lymphocytes.
Communication between the cells of the immune system is not only achieved through 
direct cell-to-cell contact, mediated by specific cell surface proteins but also through 
diffusible, chemical mediators called cytokines. These secreted cytokines have several 
advantages over direct cell-cell interaction as they can be transported quickly to sites 
of infection and can affect target cells far from their site of release (Miller & Krangel, 
1992b).
Cytokines have several features in common. They are antigen nonspecific 
glycoproteins, synthesised and normally rapidly secreted in response to a stimulus. 
They are extremely potent mediators which interact with specific high affinity receptors 
on the cell surface. One cell can produce many different cytokines and these, in turn, 
can have multiple effects on different target cells (Oppenheim et al. 1991).
Many cytokine receptors require a receptor associated molecule in order to achieve high 
affinity ligand binding and/or transmission of cytoplasmic signals. Some of these 
receptor associated molecules are shared by different cytokine receptors. A common 
event in the cytokine system is the phosphorylation of the cytokine receptors and of 
various cytoplasmic proteins. Many of the cytokine receptor associated molecules are 
yet to be identified and how binding of cytokines to their receptors transmit intracellular 
signals is still very unclear (Taga & Kishimoto, 1992).
Recently, a large superfamily of structurally and functionally related cytokines has been 
identified and named the chemokine superfamily. It consists of a number of 5 - 10 
kilodaltons (kDa) pro-inflammatory proteins that show 20 - 50 % homology at the 
amino acid level and display four conserved cysteine residues near the N - terminus. 
This superfamily has been subdivided into two subfamily branches. The C-X-C 
chemokine subfamily has an intervening amino acid residue between the first and 
second of the four conserved cysteine residues, while the C-C chemokine subfamily of 
proteins does not have this intervening amino acid (Oppenheim et al. 1991).
In the course of studying peptides released by alpha granules of platelets, haematologists 
were the first to encounter a member of this superfamily. Platelet factor 4 (PF4) was 
the first protein of this superfamily to be characterised, in 1977 (Deuel et al. 1977). 
PF4 is stored in platelet-a granules along with other proteins including two other C-X-C 
proteins, platelet basic protein (PBP) and its N-terminal truncation derivative, 
connective tissue-activating peptide III (CTAP-III). B-thromboglobulin (fl-TG), a 
truncation derivative of PBP and CTAP-III, was characterised early on (Castor et al. 
1983; Holt & Niewiarowski, 1989). Immunologists then reported the induction of gene
expression for a peptide homologous to these platelet proteins in interferon- 7  (IFN-7 ) 
stimulated macrophages and named the peptide IP-10. Unlike the C-X-C proteins stored 
in the platelet, IP-10 was found to be induced in cells upon stimulation, and IFN- 7  is 
particularly potent (Luster & Ravetch, 1987).
This area of research was quiet until several related proteins were found that are 
strongly chemotactic for leukocytes (Baggiolini et al. 1989). After the discovery of 
interleukin- 8  many research groups entered the field and soon the knowledge about C- 
X-C proteins increased enormously (Mazurov et al. 1988; Yoshimura et al. 1987; Walz 
etal. 1987).
The structure of the first C-C protein was deduced from the cDNA of the LD78 gene 
which was cloned by subtractive hybridisation from human tonsilar lymphocytes (Obaru 
et al. 1989). Information on biological activities was obtained when two proteins from 
murine macrophages, macrophage inflammatory protein (MIP) la  and IB, were isolated 
(Wolpe et al. 1988; Sherry et al. 1988). Monocyte chemotactic protein-1 (MCP-1) was 
isolated from several human sources, and shown to be chemotactic for monocytes, but 
not for neutrophils (Yoshimura et al. 1989; Matsushima et al. 1989). Other related 
proteins which, like MCP-1, act on mononuclear cells, 1-309 and RANTES, were then 
isolated and characterised (Miller et al. 1989; Schall et al. 1988; Schall et al. 1990; 
Miller & Krangel, 1992a).
To date, at least ten C-C chemokines and thirteen C-X-C chemokines have been 
identified, either at a cDNA level or a protein level (Table 1.1) (Baggiolini et al. 
1994).
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Table 1.1 Human Chemokines
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The two subfamilies can also be distinguished by their target cell specificity as the C - 
X - C chemokines act primarily as potent chemoattractants and activators of neutrophils 
although there are some exceptions. IP-10 attracts only monocytes, T lymphocytes and 
natural killer cells (NK cells) (Yatani et al. 1987; Kaplan et al. 1987). C-C 
chemokines attract monocytes, T lymphocytes, basophils and eosinophils (Baggiolini et 
al. 1994). This specific targeting of leukocyte populations may be of potential 
therapeutic interest.
The chromosomal location of the chemokine genes is also another way of subdividing 
the superfamily. C-X-C chemokine genes are localised on chromosome 4 (ql2 - q21) 
and the C-C chemokine genes at chromosome 17 (q ll - q21) (Donlon et al. 1990).
In the last year, a protein that is a chemoattractant for T lymphocytes has been 
identified and named lymphotactin. Lymphotactin has sequence homology with both 
subfamilies of the chemokine superfamily and only has two of the four conserved 
cysteine residues. The chromosomal location is also different with the gene for human 
lymphotactin being located on human chromosome 1. This suggests the existence of 
a third subfamily of chemokines (Kelner et al. 1994; Kennedy et al. 1995).
1.2 RANTES
1.2.1 Gene and Protein Structure
The discovery of RANTES occurred during the search for genes that had interesting 
expression properties, genes that were only expressed in T lymphocytes. In 1988, 
Schall et al, using a subtractive hybridisation method, produced a T lymphocyte minus 
B lymphocyte cDNA library. This library was then screened with a radioactive cDNA 
probe which had been prepared by subtracting cDNA from a growth factor dependent 
T lymphocyte cell line after antigen stimulation from B lymphoblastoid cDNA. This 
produced genes that would only be present after activation of T lymphocytes. A gene 
was identified using this method and was named RANTES, regulated on activation, 
normal T cell expressed and secreted (Schall et al. 1988).
In situ hybridisation experiments and analysis of somatic cell hybrids with a cDNA 
probe to the gene were performed. The gene is localised to the human chromosome 17 
(q 11.2 - 12), as are all known C-C chemokine genes (Donlon et al. 1990). The 
RANTES gene spans approximately 7.1 kilobases (kb) which makes it the largest C-C 
chemokine gene identified. It consists of three exons of 133, 112 and 1075 bases, and 
two introns of 1.4 and 4.4 kb. The first exon contains the 5’ untranslated region and 
the nucleotides that code for the signal sequence, the second exon encodes for the 
amino-terminal end of the mature protein and the third exon, the carboxyl-terminal and 
the 3’ untranslated region (Nelson et al. 1993).
Over twenty potential binding sites for transcription factors were detected in the 
immediate upstream region of the RANTES gene e.g. consensus sites for AP-1, NFkB,
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CD28RE and NFIL6  (Nelson et al. 1993; Ortiz et al. 1996). These regulatory sites 
were originally described in promoters from various cells not just T lymphocytes, 
including fibroblasts and some are known to be sites for factors that are responsive to 
different second messenger stimulation such as an AP-1 binding site (Lamb & 
MvKnight, 1991). The presence of these sites does not necessarily mean that they are 
important in RANTES expression but it does suggest that there will be many 
transcriptional controls.
The cDNA encodes a polypeptide of 91 amino acids which has no potential sites for N - 
linked glycosylation and includes an amino-terminal signal sequence of 23 amino acids. 
After cleavage of the signal sequence the mature secreted protein consists of 6 8  amino 
acids. The peptide is basic with an isoelectric point (pi) of 9.5 (Schall et al. 1988).
The RANTES peptide was expressed in the human embryonic kidney cell line 293. The 
peptide is a recombinant 8  kDa molecule, which is consistent with the predicted size 
of the peptide after the signal sequence has been removed (Schall et al. 1990). To date, 
the three dimensional structure of only five human chemokines has been published 
including RANTES. The basic monomer structure of each chemokine is similar 
consisting of a three stranded anti-parallel 6 -pleated sheet overlayed by a carboxy 
terminal a helix. The conserved cysteine residues are joined by two disulphide bridges 
in a 1-3 and 2-4 motif (Chung et al. 1995).
However, the aggregation state and oligomeric structures observed by NMR 
spectroscopy and X-ray are different. Initially the three dimensional structure for 
RANTES was generated assuming that it would be a monomer at the concentrations
used, but the spectra produced proved that this was an incorrect assumption. There is 
also evidence from gel filtration experiments that RANTES exists as a dimer in solution 
at higher concentrations (Paolini et al. 1994). The RANTES dimer forms an elongated 
prolate ellipsoid with the two monomers being superimposable (Chung et al. 1995). 
This is very similar to the three dimensional structure of MIP-lfl but not similar to the 
compact structure of the C-X-C chemokines such as IL- 8  (Lodi et al. 1994; Clore & 
Gronenbom, 1995). It is interesting that the dimer arrangements of all the chemokines 
appears to subdivided the superfamily into its two branches. However, it is uncertain 
whether the chemokines act as monomers or dimers at their receptors so the three 
dimensional structure differences may not be responsible for the cell-type specificity of 
the two subfamilies. It is more likely due to receptor-ligand contacts.
1.2.2 Cellular Sources of RANTES
Northern blot analysis has been used to identify RANTES gene expression. The 
RANTES mRNA was first shown to be expressed in several growth factor (interleukin- 
2) dependent T lymphocyte cell lines but not in all T lymphocyte or B lymphocyte 
tumour cell lines. Stimulation of one T lymphocyte cell line actually leads to a 
reduction in RANTES expression (Schall et al. 1988).
RANTES mRNA expression in peripheral blood mononuclear cells (PBMC) is 
detectable at low levels but these levels increase after antigen stimulation or 
phytohaemagglutinin (PHA) stimulation, after about five days incubation (Schall et al. 
1988). However, another group could detect RANTES expression in resting PBMC 
easily but were unable to detect changes after antigen stimulation even after seven days
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(Miller et al. 1989). These conflicting results could be due to differences in methods 
for preparation of the PBMC, as RANTES expression could possibly be upregulated 
during the preparation stages.
In the last four years, studies have shown that T lymphocytes are not the only source 
of RANTES. A wide range of cell types express RANTES including natural killer 
cells, renal mesangial and epithelial cells, human lymph nodes, tumours, fibroblasts, 
and vascular smooth muscle cells (Table 1.2).
Table 1.2 RANTES mRNA Tissue Expression
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1.2.3 Receptor - Characterisation
The first step in chemokine activation of inflammatory cells involves binding of the 
chemokine to specific cell surface receptors. The increasing availability of purified 
recombinant chemokines has made the identification and molecular cloning of 
chemokine receptors possible. In the last four years five different C-C chemokine 
receptors have been identified.
cDNA has been isolated, from haematopoietic cells, that encodes a receptor for 
RANTES which binds M IP-la, RANTES, MCP-1 and MCP-3 with varying affinities 
(Gao et al. 1993; Neote et al. 1993; Combadiere et al. 1995b). It conforms to the 
classical seven transmembrane spanning domain architecture of a G protein coupled 
receptor. This is also consistent with the fact that many functions of the C-C 
chemokines can be blocked by pertussis toxin. Transcripts for this MIP-la/RANTES 
receptor have been detected in HL60, U937, THP-1 cell lines and human B 
lymphocytes but not detected in total RNA from activated human T lymphocytes or T 
cell lines. Also, using binding studies and functional assays, the MIP-la/RANTES 
receptor has been identified on monocytes and on a differentiated HL60 cell line (Van 
Riper et al. 1993; Wang et al. 1993; Van Riper et al. 1994). It is now generally 
accepted that all these studies are referring to one G protein coupled receptor known 
as C-C CKR1, which binds M IP-la, MCP-1 and RANTES. Although the binding 
affinities for the chemokines differ depending on the cells examined.
A C-C CKR2 has also been identified on THP-1 cells and MonoMac6 , another 
monocytic cell line, which binds only MCP-1 and MCP-3. There are several variants 
of this receptor as it can be alternatively spliced at the C-terminal end (Charo et al.
1994). C-C CKR3 is an eosinophilic receptor which binds eotaxin, RANTES and MIP- 
l a  (Combadiere et al. 1995a). The most recent discovery is C-C CKR4, found on a 
human basophilic cell line, KU812. This receptor can be activated by MCP-1, M IP-la 
and RANTES (Power et al. 1995).
An ubiquitous chemokine receptor has been found on red blood cells and endothelial 
cells and lymphocytes, known as Duffy antigen (Kunkel et al. 1995). This is a 
multispecific chemokine receptor which binds chemokines from the C-X-C subfamily 
such as IL- 8  and chemokines from the C-C subfamily including RANTES and MCP-1 
(Zhao-hai et al. 1995). This appears to be the only chemokine receptor to be 
nonspecific for the two subfamilies. There is no evidence to suggest that the receptor 
is regulated by G proteins. The Duffy antigen, which is a receptor for the human 
malarial parasite Plasmodium vivax has not been shown to transduce signals and is 
thought to promote clearance of chemokines from the circulation (Horuk, 1994; Horuk 
et al. 1994).
1.2.4 Biological Activities of RANTES
1.2.4.1 Mononuclear Cells
Recombinant RANTES has been used to assess the biological effects of this chemokine. 
RANTES caused the selective migration in vitro of a subset of T lymphocytes which 
expressed the cell surface antigens , CD4 and CD45RO+ (Schall et al. 1990)(Table 
1.3). This specific isoform of CD45 is thought to be present on prestimulated or 
primed memory TH lymphocytes. These are immunologically experienced cells with
enhanced proliferative and cytokine producing potentials. RANTES can also elicit 
transendothelial chemotaxis of unstimulated primed memory T lymphocytes in a 
chemotaxis assay using human umbilical vein endothelial cell monolayers (Roth et al.
1995).
A human/severe combined immune deficient (SCID) mouse model was used to 
demonstrate infiltration of human T lymphocyte in vivo in response to RANTES. SCID 
mice received human lymphocytes followed by sequential injections of RANTES. 
Seventy two hours after injection of RANTES, both CD4+ and CD8 + migrated into the 
skin in response to RANTES (Murphy et al. 1994).
RANTES also acts as a chemoattractant for human blood monocytes and THP -1  cells 
in vitro (Wand et al. 1993; Schall et al. 1990). The first studies performed looked at 
the effects of RANTES, in solution, on monocyte migration, which is known as 
chemotaxis. More recently, the haptotaxis of monocytes was shown to be induced by 
RANTES in vitro (Wiedermann et al. 1993). Haptotaxis is defined as cell migration 
induced by surface bound chemotactic gradients. This suggests that RANTES may not 
just induce the migration of inflammatory cells in inflamed tissues, but may also cause 
these cells within the bloodstream to adhere to the endothelium and extravasate into the 
tissues. RANTES can also trigger the release of N-acetyl-fl-D-glucosaminidase, a 
granular enzyme, from monocytes that have been treated with cytochalaisin B, to 
prevent them adhering (Uguccioni et al. 1995).
From all this information a model can be proposed to explain the role of chemokines 
such as RANTES and mononuclear cells in inflammation. During the first phases of
the inflammatory response, the endothelium is activated and expresses adhesion 
molecules of the selectin family. These molecules cause leukocytes to roll along the 
vascular wall. Platelets can also degranulate, releasing RANTES which can bind to the 
activated endothelium and provide a haptotactic gradient for a specific subsets of 
mononuclear cells. As the inflammatory process continues, IL-lfl and TNF-a are 
produced, upregulating the production of chemoattractants such as IL-8 , M IP-la and 
RANTES which provide more of a chemotactic/haptotactic gradient into the 
interstitium. In combination with the induced expression of specific adhesion molecules 
of the integrin and immunoglobulin superfamilies, these chemokines lead to 
mononuclear cell extravasation. The final stage occurs, after several days, when T 
lymphocytes attracted to the inflammatory site become activated and strongly express 
RANTES as they become functionally active. This helps to amplify the immune 
response as more memory T lymphocytes are recruited to the site of inflammation (Fig. 
1.1).
1.2.4.2 Granulocytes
Neutrophil migration is not induced by RANTES (Schall et al. 1990). However, 
eosinophils are another inflammatory cell which can be activated by RANTES 
(Kameyoshi et al. 1992). RANTES is also a powerful chemoattractant of eosinophils 
in vitro, as effective as C5a (Rot et al. 1992). C5a is a component of the complement 
cascade system, part of the immune response, and a potent eosinophil and neutrophil 
chemoattractant. However, some groups have shown that eosinophils have a 
requirement for priming before migrating in response to RANTES (Schweizer et al. 
1994). This may be due to differences in chemotactic methods used by the different
groups or by variations in blood donors, some groups having used allergic subjects. 
RANTES also induces production of reactive oxygen species (an indicator of the release 
of toxic granule proteins after degranulation) from cytochalaisin-B treated cells but it 
is a weaker inducer than C5a (Kapp et al. 1994). Eosinophil transendothelial migration 
is also induced by RANTES in vitro and can be inhibited by antibodies against the B2 
integrin CD 18 adhesion complex. RANTES did not cause an increase in adhesion 
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Fig. 1.1 Model of Lymphocyte Transendothelial Migration
Basophils have also been stimulated with RANTES. The chemokine is an effective 
basophil chemoattractant but a weak stimulator of mediator release such as histamine 
and leukotrienes from these granulocytes (Kuna et al. 1993). These effects of RANTES 
on granulocytes are not necessarily always beneficial. The degranulation of eosinophils 
is responsible for some of the pathologic changes observed in allergic diseases of the 
airways or skin where the immune responses are inappropriate to the antigen challenge 
(Charlesworth et al. 1989; Schweizer et al. 1994). RANTES can also be detected in 
lymph nodes of allergic individuals (Devergne et al. 1994).
1.2.4.3 Tumours
RANTES also induces the chemotaxis in vitro of the anti-tumour cells, NK cells and 
IL-2-activated NK cells (IANK cells) (Maghazachi et al. 1994). These cells have high 
anti-tumour activity and have been used to treat murine metastases but do not disperse 
efficiently to the site of tumour growth. Therefore RANTES could be used to enhance 
the accumulation of these cells at tumour sites. This therapeutic potential for RANTES 
is also supported by the knowledge that RANTES production has been detected in solid 
tumours, suggesting it has a role in causing the selective migration of inflammatory 
cells with certain tumours (Schall, 1991).
1.2.4.4 Human Immunodeficiency Virus
Evidence has suggested that CD8 + T lymphocytes have some function in the control of 
human immunodeficiency virus (HIV) infection in vivo, either by cell mediated 
mechanisms or by the production of HIV-suppressive factors (HIV-SF). Recently,
M
Cocchi et al have demonstrated that several chemokines including RANTES can mediate 
antiviral effects and identified RANTES, M IP-la and MIP-1B as the major HIV-SF, 
produced by CD8 + T lymphocytes (Cocchi et al. 1995).
Summary
The specificity of RANTES does make it an attractive candidate for roles in conditions 
where T lymphocytes, eosinophils and basophils predominate, including auto-immune 
disease such as rheumatoid arthritis. RANTES may also play a part in T lymphocyte 
memory function due to its specific effects on memory T lymphocytes and have a role 
in potential therapies for the prevention and therapy of AIDS.
Table 1.3 Biological Activities of RANTES.
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To date, three signalling pathways have been shown to be important in T lymphocyte 
activation : i) protein tyrosine kinases (PTK), ii) phospholipase C (PLC), and iii) 
phosphoinositide 3-kinase.
The first pathway involves the binding of extracellular ligands to receptors that interact 
with PTK from the src (e.g. Lck, Fyn) and syk (e.g. Syk and ZAP70) families, causing 
an increase in tyrosine protein phosphorylation. Coupling of the T lymphocyte antigen 
receptor (TCR) to cytoplasmic tyrosine protein kinases is a property of the cytoplasmic 
domain of the receptor. Chimeric proteins containing the cytoplasmic domain of the 
CD3-zeta chain can stimulate tyrosine phosphorylation, inositol phosphate metabolism, 
calcium mobilisation and IL-2 production (Irving & Weiss, 1991). Cytoplasmic 
domains of other TCR chains have also been shown to stimulate tyrosine protein kinases 
(Letoumeur & Klausner, 1992).
The cytoplasmic domains all share a sequence motif, called a TAM (tyrosine-based 
activation motif) (sometimes referred to as the antigen-recognition activation motif, 
ARAM)(Samelson & Klausner, 1992). In resting T lymphocytes, this motif associates 
with the amino-terminus of syk kinases (Timson Gauen & Kong, 1992). Receptor 
ligation induces receptor tyrosine phosphorylation and tyrosine residues in the TAM 
motif are phosphorylated. This probably explains the subsequent binding of syk kinases 
via their src-homology (SH)2 domains to the motif (Sancho et al, 1993 ; Pawson & 
Gish, 1992), which initiates a signalling cascade resulting in lymphocyte activation.
The prior phosphorylation of the TAM may be fulfilled by the src kinases. COS cells
transfected with T cell receptor chains (CD8 -zeta) have been transiently transfected with 
cDNAs encoding for various kinases. Phosphorylation of the receptor chains and syk 
kinase recruitment was dependent upon coexpression of lyk or fyn  (Chan et al, 1992; 
Iwashima et al, 1992). In addition, T lymphocyte activation has been shown to be 
dependent upon lek by using non-responsive T lymphocyte cell lines that have no 
endogenous lek. When lek is introduced into these cells, the cells can then respond to 
signalling through the antigen receptor (Strauss & Weiss, 1992).
The second pathway, the classical phosphoinositide pathway, is activated when agonists 
bind to G protein or PTK coupled receptors, causing PLC activation and the production 
of the second messengers, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol.
The third pathway also involves phosphatidylinositol (Ptdlns) signalling, but this time 
the enzyme phosphatidylinositol 3-kinase (PI 3-kinase) is activated and the second 
messengers are 3-phosphorylated inositol lipids (D-3 phosphoinositides). Only the two 
pathways involving Ptdlns signalling were studied.
1.3.1 Classical Phosphoinositide Pathway
Initially, the investigations into Ptdlns signalling, in this study, were centred around 
the G protein coupled PLC and its substrate phosphatidylinositol 4,5-bisphosphate 
(PtdIns(4 ,5 )P2), as the receptors identified for RANTES have all conformed to the 
classical seven transmembrane spanning domain architecture of G protein coupled 
receptors (see 1.2.3). This is referred to as the classical phosphoinositide pathway
(Berridge & Irvine, 1984). Ptdlns is an acidic phospholipid mainly located in the inner 
plasma membrane. PtdIns(4,5)P2 is formed by the phosphorylation of Ptdlns by 
specific kinases. The binding of certain agonists to G protein coupled cell surface 
receptors is followed by activation of a heterotrimeric G protein. An exchange occurs 
in the a  subunit of the G protein from a GDP- to a GTP- bound state, resulting in a 
dissociation of the a subunit from the By subunits. The free a subunit can activate both 
PLC B1 and 82, whereas the free By complex activates preferentially the PLC 82. The 
activated PLCs hydrolyse the phosphodiester bond linking the phosphatidylinositol unit 
to the acylated glycerol moiety. This results in the production of two biological second 
messengers : IP3 and 1,2 - diacylglycerol (Fig. 1.2).
IP3 is a short lived messenger, lasting only a few seconds. Most cells express several 
of the five isoforms of the IP3 receptor. The human type 1 IP3 receptor has been 
detected on T lymphocytes (Hamick et al. 1995). Activation of the IP3 receptor causes 
the rapid release of Ca2+ from intracellular stores, such as the endoplasmic reticulum, 
which then may cause the observed calcium influxes from the extracellular environment, 
referred to as capacitative calcium entry, by the release of a calcium influx factor 
(Berridge, 1984; Berridge & Irvine, 1984; Berridge, 1993; Putney & Bird, 1993). The 
influx of Ca2+ is responsible for a sustained phase of Ca2+ elevation and the 
replenishment of intracellular stores. Alterations in intracellular calcium levels are 
observed after the engagement of the TCR. Diacylglycerol release is more prolonged 
and it serves as a messenger by activating protein kinase C (PKC), while remaining 
bound to the membrane (Nishizuka, 1984; Nishizuka, 1988). This enzyme then 
phosphorylates serine and threonine residues in numerous target proteins. PKC can 
activate several signalling cascades such as ERKS and JNK which are known to regulate
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transcription factors such as AP-1, which controls expression of various cytokine genes, 
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1.3.2 PI 3-Kinase
More recently, investigations have been based around the other Ptdlns signalling 
pathway which involves D-3 phosphoinositides, a family of membrane phospholipids 
which are phosphorylated at the 3-position of the inositol ring (Stephens et al.
1993)(Fig. 1.2). They were originally discovered in transformed cells but are also 
found in cells such as neutrophils, platelets, brain cells and T lymphocytes (Whitman 
et al. 1988). Only very small amounts of D-3 phosphoinositides are present in cells, 
i.e. < 0.1 % total Ptdlns lipids. The family includes phosphatidylinositol 3-phosphate 
(PtdIns(3)P), phosphatidylinositol 3,4-bisphosphate (PtdIns(3 ,4 )P2), and 
phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P3). The routes of metabolism 
of these D-3 phosphoinositides are only poorly understood when compared with those 
of the classical phosphoinositides. No phospholipase has been found that can hydrolyse 
these 3-phosphoinositides (Stephens et al. 1993). This suggests that it is the D-3 
phosphoinositides that are the signalling molecules and not any breakdown products as 
in the case of the classical phosphoinositides.
1.3.2.1 PI 3-Kinase Isoforms
D-3 phosphoinositides are the in vitro products of a growing family of enzymes referred 
to as PI 3-kinases (Fry, 1994) :
i) PTK/SH2 linked isoform : a heterodimer of a 85 kDa regulatory subunit (p85a,B) 
(Otsu et al. 1991) and a 110 kDa catalytic subunit (pi 10a,B) (Hiles et al. 1992; Fry,
1994). The p85 subunit possesses two Src homology 2 (SH2) domains, one SH3 
domain, and two proline rich regions (Otsu et al. 1991). These may facilitate numerous
protein-protein interactions. Consensus binding motifs for the SH2 domains, YXXM, 
are found in the intracellular domains of receptor tyrosine kinases such as the PDGF 
B - receptor; at several positions in intracellular substrates such as insulin receptor 
substrate - 1(IRS-1); in cytosolic receptor linked protein tyrosine kinases such as c-Src; 
and in cell surface receptors such as CD28 (see 1.4). Binding of Src-family kinases 
(such as Lyn and Fyn) via SH3 domains to the proline rich regions on p85 has also 
been proposed to activate PI 3-kinase via receptor tyrosine kinases (Pleiman et ah 
1994). This isoform can use Ptdlns, PtdIns(4)P and PtdIns(4,5)P2 as its substrates in 
vitro.
ii) PI 3-kinasey isoform : is G protein By subunit responsive and has been detected in 
human neutrophils, U937 cells and platelets (Stephens et ah 1994; Thomason et ah 
1994). This also explains pertussis toxin inhibiting G protein receptor coupled PI 3- 
kinase activity as GBy is derived from the pertussis toxin sensitive Gi and/or G0 
(Stephens et ah 1994). The molecular structure of the G protein sensitive PI 3-kinase 
has not been defined. The previously identified p85/pll0 PI 3-kinase heterodimer 
could be activated by GBy as well as by phosphotyrosine. Or there may be another 
distinct isoform of PI 3-kinase (Stephens et ah 1994). The first option seems more 
likely as formylmethionylleucylphenylalanine peptide (FMLP) activation of neutrophils 
can be completely inhibited by both pertussis toxin and wortmannin (Thelen et ah
1994). This isoform can use Ptdlns, PtdIns(4)P and PtdIns(4,5)P2 as its substrates in 
vitro.
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iii) Ptdlns-specific isoform : a heterodimer of a 110 kDa and 150 kDa subunit in vivo. 
This isoform has a substrate specificity for Ptdlns only and is the mammalian homolog 
of a yeast enzyme, Vps34, which also only phosphorylates Ptdlns (Volinia et al. 1995).
Unless otherwise stated PI 3-kinase refers to the PTK/SH2 linked isoform.
1.3.2.2 Downstream Targets
The downstream targets of the D-3 phosphoinositides are still unclear. The homology 
of Ptdlns-specific PI 3-kinase isoform with Vps34, which is involved in vacuolar 
processing and protein trafficking, suggests that Ptdlns-specific PI 3-kinase and PI(3)P 
in mammalian cells could be involved in vesicular trafficking. The role of 
PtdIns(3,4)P2 is unknown. It may be a breakdown product in certain systems but in 
other systems a PtdIns(3)P 4 - kinase has been described suggesting that PtdIns(3,4)P2 
may have a functional role (Graziani et al. 1992).
An important tool in the clarification of PtdIns(3,4,5)P3 function is wortmannin. 
Wortmannin is a fungal metabolite which is cell permeant. It has been demonstrated 
to be a potent inhibitor of PI 3-kinase (Yano et al. 1993; Woscholski et al. 1994) and 
is a non-competitive inhibitor with respect to ATP or Ptdlns and binds irreversibly to 
the p i 10 catalytic subunit (Arcaro & Wymann, 1993). Protein kinases A, C and G, 
phosphatidylinositol 4-kinase and Vps34 have also been reported not to be inhibited by 
wortmannin at concentrations of up to 1 /xM (Arcaro & Wymann, 1993; Yano et al. 
1993). Although a soluble form of PI 4-kinase has recently been shown to be inhibited 
by wortmannin at low concentrations (Nakanishi et al. 1995), and in vitro PLA2 can be
inhibited partially by wortmannin (Cross et al. 1995), it is still considered as a specific 
PI 3-kinase inhibitor. In addition, there is one report which shows that wortmannin 
inhibits receptor - mediated activation of phospholipase D (PLD). The maximum 
inhibition of PLC, at concentrations as high as 1 /xM, is 50 %. Also, this PLD 
inhibition could be accounted for by an indirect effect with PI 3-kinase acting upstream 
of PLD (Gelas et a l  1992) (Table 1.4).
Table 1.4 Summary of Concentration of Wortmannin Required to Inhibit Enzvmes
Kinase Wortmannin IC50 (jiM )
PTK/SH2-coupled PI 3-kinase < 0 . 0 1
Mammalian Ptdlns 4-kinase
- membrane bound > 1
- soluble 0.05
p l a 2 0 . 0 0 2
PKC ~  1 0
PLD > 0 . 0 1
Wortmannin has been used to great effect to identify the processes in which D-3 
phosphoinositides are involved and any potential downstream targets. There are at least 
three main downstream target molecules particularly relevant to T lymphocyte 
activation:
i) Protein kinase C isoenzymes
D-3 phosphoinositides can activate PKC isoenzymes such as PKC5, e , £ and rj 
(Nakanishi et al. 1993; Toker et al. 1994). PKC regulates many signalling pathways,
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including those mediated by Ras, mitogen-activated protein (MAP) kinases such as 
extracellular signal regulated kinases (ERKS) and c-Jun N-terminal kinase (JNK)(Pastor 
et al. 1995). There is also circumstantial evidence to suggest that PKC isoforms could 
mediate mitogenic effects of the PI 3-kinase pathway, as PKCf has been reported to be 
critical for mitogenic signal transduction in fibroblasts and a dominant negative PKCf 
subspecies blocked NF-kB activation (Berra et al. 1993; Diaz-Meco et al. 1993).
ii) GTP-binding proteins
The Ras GTPases are a superfamily of small GTP-binding proteins which have been 
subjected to intensive study because activated mutants of these genes have been found 
in a large number of human tumours. A subgroup of this superfamily are the Rho 
GTPases - Racl and Rac2, Rho A, B, C and G, Cdc42, and TC10 (Boguski & 
McCormick, 1993). They function as molecular switches, and are on in the GTP-bound 
state, off in the GDP-bound state.
Ras stimulates both the Rac and ERKS but Rac is also activated by receptor tyrosine 
kinases through PI 3-kinase although the exact signalling pathways are still unclear (Hu 
et a.l 1995). Rac controls several signalling pathways including the organisation of the 
actin cytoskeleton by induction of lamellipodia and membrane ruffling (Zigmond 1996), 
activation of p21-associated kinases (PAK)(Manser et al. 1994), activation of the JNK 
pathway and stimulation of arachidonic acid metabolism, which leads to Rho activation 
(Macara et al. 1996). Rho activation can then lead to activation of PI 3-kinase (Zhang 
et al. 1993), activation of PI 5-kinase (Chong et al. 1994), activation of a putative 
MAP kinase module and phospholipase D activation (Macara et al. 1996). The 
different signalling pathways activated by the various Rho
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GTPases are integrated at the level of transcription factors.
Constitutively active Rho is weakly transforming in NIH 3T3 fibroblasts and Rac and 
Rho have also been shown to be essential for transformation by Ras, which has 
suggested a role for Rho family members in controlling cell proliferation. The 
signalling pathways used by Rac and Rho to control cell proliferation still remain to be 
identified. Many of the enzymes activated downstream of Rho including PI 3-kinase 
and PI 5-kinase are thought to have a role in growth control (Zhang J. et al, 1993;
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Fig. 1.3 Rho family GTPases
iii) p70s6K
The S6  ribosomal protein , which is necessary for cells to enter the S-phase of the cell 
cycle after mitogen stimulation, is phosphorylated by p70 S6  kinase (pTO^) (a 
serine/threonine kinase) (Kozma & Thomas 1994). Initially p70S6K in vitro was shown 
to be inhibited unless phosphatase inhibitors were present and treatment with protein 
phosphatase-2A led to inactivation, suggesting that phosphorylation by a 
serine/threonine kinase was involved in regulating p70S6K activity (Ballou et al. 1988). 
Recently Kozma et al have shown that phosphorylation of Ser/Thre residues does 
accompany p70S6K activation (Kozma et al, 1993).
An important tool in the identification of upstream regulation of p70^K is rapamycin. 
This inhibits T lymphocyte activation by blocking the G1 phase of the cell cycle (Kunz 
& Hall 1993) and selectively prevents the activation of p70S6K (Terada et a l , 1993). 
Rapamycin does not inhibit the MAP kinase cascade. Rapamycin causes the 
dephosphorylation of p70S6K at sites that are phosphorylated in response to stimuli that 
activate p70S6K (Han et al, 1995). Interestingly, wortmannin and SQ20006 (a 
methylxanthine, inhibitor of cAMP-phosphodiesterase) also cause the dephosphorylation 
of these sites, although the action of this third inhibitor does not seem to be related to 
increased levels of cAMP and may be as a result of the inhibition of a protein kinase 
upstream. Rapamycin and SQ20006 both inhibit the activation of p70s6K by phorbol 
esters, whereas wortmannin does not (Han et al, 1995).
The mechanism of action of rapamycin is still unclear, rapamycin binds to a protein 
known as FKBP12 (FK506-binding protein 12 (FK506 is another immunosuppressant)) 
and it is the resulting complex that interacts with the target protein, mTOR (also called
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FRAP)(Sabatini et al, 1995). Rapamycin blocks the autophosphorylation of mTOR, 
suggesting that the kinase activity of mTOR is necessary for its role in activating p70S6K 
(Brown et al, 1995). However, wortmannin does not inhibit this autophosphorylation 
of mTOR. mTOR has not been shown to phosphorylate p70S6K but as rapamycin 
decreases the phosphorylation of p70S6K, a protein kinase or phosphatase is likely to be 
involved between mTOR and p70s<5K. Very little is known about the links that connect 
cell surface receptors to the rapamycin sensitive steps. Use of Raf and Ras dominant 
negative mutants have indicated that they are not involved in the activation of p70s6K 
(Ming et al, 1994).
Work by Chung et al, including experiments with wortmannin have shown that PI 3- 
kinase was involved in p70s6K activation (Chung et al, 1994). Other evidence for its 
involvement has come from experiments showing that the synthesis of a constitutively 
active PI 3-kinase caused activation of p70s6K (Weng et al, 1995) and the involvement 
of protein kinase B (PKB). PKB can be activated by PI(3)P and activation of PKB by 
PDGF or insulin can be inhibited by wortmannin, suggesting that PKB lies downstream 
of PI 3-kinase (Franke et al, 1995; Kohn ef al, 1995). Furthermore, activation of PKB 
is sufficient to activate p70s6K, placing PKB upstream of p70S6K (Burgering & Coffer
1995). Along with the previous evidence that phorbol ester activation of p70s6K is not 
affected by wortmannin, this would suggest that PKB is either upstream of, or acts in 











Fig. 1.4 Activation of dTO86*
1.3.2.3 Serine/Threonine Protein Kinase Activity
PTK/SH2 coupled PI 3-kinase is a dual specificity kinase and not only phosphorylates 
phosphoinositides, but the p i 1 0  subunit can act as a serine/threonine protein kinase. 
To date, only two substrates have been identified : the p85 subunit, causing a decrease 
the lipid activity of the enzyme suggesting a form of auto-regulation, and insulin 
receptor substrate-1 (IRS-1) (Lam et al. 1994). The G protein sensitive PI 3-kinase has 
not been shown yet to possess serine/threonine kinase activity. This could potentially 
differentiate between the activation of the PI 3 - kinase pathway by G proteins versus 
its control by tyrosine kinases.
A full understanding of this family of PI 3-kinases is likely to take some time due to 
the complexity of the numerous interactions which appear to take place between the 
various signalling molecules.
1.3.3 RANTES and Signal Transduction
RANTES signalling is, as yet, poorly understood. All of the chemokine receptors 
identified belong to the superfamily of G protein linked receptors containing seven 
transmembrane spanning domains, which is consistent with the fact that many of the 
functions of these chemokines can be blocked by pertussis toxin. This includes the 
recently discovered C-C CKRs.
The C-C CKR1 is G protein linked and Ca2+ mobilisation is detected after M IP-la, 
MCP-3 or RANTES stimulation (Combadiere et al. 1995b). However, some groups 
have observed RANTES stimulation of C-C CKR1 on monocytic cells inducing
migration without Ca2+ mobilisation, suggesting that a measurable Ca2+ mobilisation 
is not always necessary for the functional effects of RANTES and that another 
signalling pathway apart from the classical phosphoinositide pathway is involved (Van 
Riper et al. 1993). This is contradicted by others who were able to detect Ca2+ 
mobilisation (Wang et al. 1993). This can be explained by differences in experimental 
methods, e.g., the use or absence of serum in the vehicle, the use of different 
monocytic cells, THP-1 cell line or freshly prepared monocytes, and different methods 
for assessing migration.
There is also evidence to show that C-C CKR2 is G protein linked and activation of the 
receptor leads to calcium mobilisation (Myers et al. 1995). C-C CKR3 is pertussis 
toxin sensitive suggesting the involvement of a G£ protein (Kapp et al. 1994) and leads 
to intracellular Ca2+ mobilisation (Rot et al. 1992). The signalling pathways connected 
to C-C CKR3 have been studied further, and staurosporine, an effective inhibitor of the 
phospholipid/Ca2+ dependent PKC and wortmannin completely abrogated the production 
of reactive oxygen species induced by RANTES (Bourne et al. 1995; Kapp et al. 1994). 
This again illustrates the complexity of RANTES signalling. Finally, activation of the 
C-C CKR4 by RANTES induces a rapid change in intracellular Ca2+ levels, as well 
as histamine release and cell migration which are all pertussis toxin sensitive (Bischoff 
et al. 1993).
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1.4 T Lymphocyte Activation and The Costimulatorv Concept 
The signals generated through engagement of the TCR by foreign antigen associated 
with self MHC (Ag-MHC) are not sufficient for full activation of T lymphocytes and 
the cells enter into a state of proliferative hyporesponsiveness {in vitro this is referred 
to as anergy and in vivo, tolerance), or the cells may undergo programmed cell death 
(PCD)(Bretscher, 1992). Another signal is required for IL-2 production and 
proliferation, giving rise to the two signal hypothesis, where engagement of the TCR, 
leading to PTK dependent activation of Ras and PLC signalling pathways, provides 
signal 1 (Pastor et al. 1995; Fraser et al. 1992; Metzner et al. 1994). Signal 2 is still 
not completely identified but there are several possibilities : i) it may be a unique signal 
activating distinct signal transduction pathways which complement those activated by 
TCR, ii) it may be the same as signal 1 but occur at different time points or in different 
cellular compartments, or iii) it may be the same as signal 1 but act in an additive 
fashion by enhancing the amplitude or duration of signal 1 , and thus crossing a 
threshold and activating downstream signalling cascades.
Signal 2 is provided by costimulatory molecules on antigen presenting cells. The major 
costimulatory signal involved in T lymphocyte activation is provided by the interactions 
of the CD28 cell surface antigen on the T lymphocyte and its ligands, the B7 family, 
on the antigen presenting cell (APC) (Linsley et al. 1991a; Linsley et al. 1991b). This 
has been confirmed by the use of CD28-deficient mice where responses to mitogens 
were impaired, although T lymphocyte development was normal (Fig. 1.5)(Shahinian 
et al. 1993).
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As predicted by the two signal hypothesis, CD28 ligation alone has little effect on 
resting T cell proliferation, but controls proliferation and IL-2 production from TCR 
stimulated CD28+ T cells (Linsley et al. 1991a). Costimulation via CD28 also 
mediates upregulation of other cytokines including IL-4, IL-8 , IL-13, 7 -interferon and 
granulocyte/macrophage colony stimulating factor (GM-CSF) (Bailey et al. 1994; Minty 
et al. 1993; Wechsler et al. 1994; Seder et al. 1994).
The cytoplasmic domain of CD28 does not have any intrinsic enzymatic activity and 
therefore must signal through the recruitment of cellular enzymes. This has analogy 
with TCR signalling where intracellular PTK such as fyn, lck and ZAP-70 are 
recruited. The cytoplasmic domain of CD28 contains a motif, Y173MNM, similar to the 
SH2-binding motif, YXXM (Songyang et al. 1993), which is a potential site for binding 
of the SH2 domains present in the p85 regulatory subunit of PI 3-kinase, after tyrosine 
phosphorylation at position 173 by an unidentified kinase (Stein et al. 1994; Prasad et 
al. 1994; Truitt et al. 1994). CD28 also contains two proline rich motifs which 
conform to a SH3 binding consensus sequence and could also lead to interactions with 
PI 3-kinase (Johnson & Gomez-Cambronero, 1995). Many reports show association 
of CD28 with PI 3-kinase and site-specific mutagenesis of 173Y to 173P disrupts the SH2 
binding motif and prevents costimulatory activity in some models (Ward et al. 1993; 
Pages et al. 1994; Sansom et al. 1995; Cai et al. 1995). Wortmannin has also been 
used to show that PI 3-kinase is pivotal in CD28 costimulation (Ward et al. 1995). 
However, other studies have revealed that PI 3-kinase is unimportant in CD28 
costimulation (Truitt et al. 1995).
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CD28 costimulation inhibits IL-2 mRNA degradation and can regulate many 
transcription factors e.g. NFkB, c-Rel and AP-1 (Rincon & Flavell, 1994). There is 
evidence to suggest that PI 3-kinase is the link between CD28 costimulation and the 
regulation of these transcription factors, since downstream targets of PI 3-kinase such 
as p70s6K (Downward, 1995), PKC isoforms (Hosaka et al. 1994; Toker et al. 1994) 
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Fig. 1.5 Costimulation of T Lymphocytes by APC
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1.5 Aims
The purposes of this study were to
a) examine the effects of RANTES on in vitro migration of T lymphocytes, not 
only analyzing migratory effects but looking at two effects that precede 
migration, shape change and actin polymerisation. To this end, T lymphocytes 
from several sources were used - primary T lymphocytes, T lymphoblasts and 
the Jurkat T cell line.
b) investigate the role of the classical phosphoinositide signalling pathway in 
RANTES stimulation of T lymphocytes by analyzing calcium mobilisation and 
Ptdlns metabolism.
c) evaluate the involvement of the PI 3-kinase signalling pathway in RANTES 
stimulation of T lymphocytes by analyzing Ptdlns metabolism, in particular the 
effects RANTES has on the activity of PI 3-kinase and the production of D-3 
phosphoinositides, and by using the PI 3-kinase inhibitor, wortmannin.
d) assess the role RANTES plays in T lymphocyte functions, other than migration, 






Plastics (sterile, cell culture grade) were purchased from Becton Dickinson (Plymouth, 
U.K.). Heparin (Monoparin™, heparin sodium (mucous), 5000 units/ml) was 
purchased from FISONS (Loughborough, U.K.) and stored at 4°C. RPM I1640, sterile 
culture medium, was purchased from Life Technologies Inc. (Paisley, U.K.), 
supplemented with 5 /xg/ml fungizone and 20 Units/ml of penicillin and streptomycin, 
and stored at 4 °C in the dark. Lymphoprep™, specific gravity of 1.077, was 
purchased from Nycomed (Birmingham, U.K.) and stored in the dark at 4 °C. 
Phosphate buffered saline (PBS)(sterile, without calcium and magnesium, 10X) was 
bought from Life Technologies Inc. (Paisley, U.K.), stored at room temperature and 
diluted to IX with sterile water. Heat inactivated bovine serum (HIBS) was either 
purchased from Life Technologies Inc. (Paisley, U.K.) already heat inactivated or non­
inactivated serum, from the same source, was inactivated by heating at 56 °C for 30 
minutes, then stored at -20 °C. R+D  human T cell enrichment columns were 
purchased from R+D (Abingdon, U.K.). Phytohaemagglutinin (PHA-P) was purchased 
from Sigma (Poole, U.K.), and made up to a 1 mg/ml sterile solution with sterile 
water, then stored at - 20°C. Trypsin/EDTA (0.5 mg/ml trypsin, 0.2 mg/ml EDTA) 
was purchased from Life Technologies Inc. (Paisley, U.K.) and stored at - 20 °C. 
Dulbecco’s modified Eagle’s medium (DMEM), sterile culture medium, was purchased 
from Life Technologies Inc. (Paisley, U.K.), supplemented with 5 /xg/ml fungizone and
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20 Units/ml of penicillin and streptomycin, and stored at 4 °C in the dark. Hank’s 
balanced salt solution (HBSS, sterile, 10X) was purchased from Life Technologies Inc. 
(Paisley, U.K.). A IX solution was prepared by adding 900 mis sterile water to the 
100 mis 10X solution, then 4.9 mis sterile 7.5 % sodium bicarbonate solution was 
added to give a pH of 7.3.
The preparation of cells and sterile experiments were all performed in class 2 sterile 
cabinets. The cell cultures were incubated at 37 °C in a humidified 5 % CO2 incubator.
2.1.2 General Reagents
Polyvinylpyrrolidine (PVP) free polycarbonate filter ( 8  fim pore size) membranes were 
purchased from Costar (High Wycombe, U.K.) Diff-Quik was purchased from Browne 
(Newbury, U.K.). FITC-phalloidin (fluorescein thiocyanate conjugated phalloidin) was 
purchased from Sigma (Poole, U.K.), and made up to a stock solution of 30 /zM in 
sterile PBS, then stored in the dark at - 20 °C. Fura-2 acetoxymethyl ester was 
purchased from Molecular Probes (Eugene, OR, USA) and stored at 5 mM in 
anhydrous DMSO, at - 20 °C, in the dark. Protein A Affigel beads were purchased 
from BIO-RAD (Hemel Hempstead, U.K.) and stored at 4 °C. Wortmannin was 
dissolved in ethyl acetate to a concentration of 20 mM and stored in aliquots at - 20 °C 
in the dark. Before use, the stock was diluted in culture medium or buffer, to the 
desired concentrations. Scintillation fluid (Optiphase) was purchased from FISONS 
(Loughborough, U.K.).
All solvents were purchased from FISONS (Loughborough, U.K.)
All other chemicals were bought from Sigma (Poole, U.K.), unless otherwise stated.
2.1.3 Antibodies and Cytokines
IL-2 was purchased from Genzyme (West Mailing, U.K.) and stored at 20 /zg/ml in 
sterile RPMI 1640, at 4 °C. Before use, the stock was diluted in culture medium to 
the desired concentrations. UCHT1, mouse anti-human CD3, was a kind gift from 
Doreen Cantrell (ICRF, London, U.K.). UCHT1 was stored in sterile PBS at 1 mg/ml. 
Long term storage of UCHT1 was at - 70 °C , while the working aliquots were stored 
at 4 °C. Before use, the stock was diluted in culture medium to the desired 
concentrations. Goat anti-mouse IgG (conjugated to phycoerythrin) was purchased from 
Dako (High Wycombe, U.K.) and stored at 4 °C. Mouse anti-human CD4, CD8 , 
CD11, CD16, CD19, CD25 (FITC-conjugated), CD45RO, CD45RA were all purchased 
from Sigma Immunochemicals (Poole, U.K.) and stored at 4 °C. Human RANTES 
was purchased from Peprotech (Rocky Hill, NJ, USA) and stored at 100 /zg/ml at - 20 
°C in sterile water. Before use, the stock was diluted in culture medium to the desired 
concentrations. Rabbit polyclonal anti-human PI 3-kinase was purchased from UBI 
(New York, NY, USA) and stored at - 20 °C. anti-human RANTES, mouse 
monoclonal and goat polyclonal, were both purchased from R+D (Abingdon, U.K.) 
and stored at 500 /xg/ml in sterile PBS/0.1 % BSA, at - 20 °C.
2.1.4 Radioisotopes
[7 -32P] labelled ATP ([32P]-ATP) (5 /zCi/ml, 3000 Ci/mmol, in aqueous solution) and 
[32P] labelled orthophosphate (32Pj) (5 mCi/ml, 8500 - 9120 Ci/mmol) were purchased 
from DuPont NEN (Stevenage, UK). pH] thymidine (1 mCi/ml, 2 Ci/mmol) was 
purchased from Amersham (Little Chalfont, U.K.).
2.1.5 Solutions
The composition of CHO-DMEM, IX NP40 lysis buffer and lipid kinase buffer were 
as follows :
CHO-DMEM - 100 ml 10X DMEM
100 mlHIBS
50 ml sodium bicarbonate (7.5 %)
25 ml 1 M HEPES
20 ml nucleoside solution [1 mM adenosine, cytidine, 
uridine, thymidine, and guanosine in sterile water, 
sterile filtered before use] 
and 800 ml sterile H20 .
Stored at 4 °C for up to two months.
IX NP40 lysis buffer - 1 % NP40 solution
100 mM NaCl 
10 mM iodoacetamide 
10 mM NaF
10 mM Tris pH 7.4 in sterile H20  
Stored at 4 °C for up to two months.
lipid kinase buffer - 5 mM MgCl2
0.25 mM EDTA
20 mM HEPES (sodium salt) pH 7.4 in sterile H2OStasd 
Stored at 4 °C for up to two months.
2.2 Human Peripheral Blood Mononuclear Cell Preparation
Human peripheral blood mononuclear cells (PBMC) were isolated from venous blood 
which had been collected from healthy donors of either sexes. The blood was collected 
from donors aseptically into a 50 ml sterile disposable syringe using a H butterfly " 
cannula (19 - 23 gauge needle). Sterile heparin was used as an anti-coagulant (10 Units 
heparin/ml blood). Alternatively, whole blood packs were purchased from the Blood 
Transfusion Service (Bristol, U.K.). The blood was decanted into sterile tubes, 
centrifuged (1860 g, 6  min, 4°C), and the plasma was removed with a sterile plastic 
pipette (Bacon et al. 1988).
The blood was then diluted four-fold with RPMI 1640 and gently mixed in a sterile 75 
cm2 flask. The diluted blood (35 ml) was layered onto 15 ml Lymphoprep ™ in sterile 
50 ml tubes at room temperature. Mononuclear cells were separated by centrifugation 
(460 g, 30 min, 20°C). The mononuclear cell layer was removed using a sterile 
pastette. Aliquots of 15 ml mononuclear cell suspension were placed in sterile 50 ml 
tubes and 30 ml sterile phosphate buffered saline (without calcium and magnesium) 
(PBS) was added to each tube. The tubes were centrifuged at 450 g for 7 minutes, 
room temperature, and the supernatants discarded. The cell pellet was washed twice 
by resuspension in 50 ml RPMI 1640 and centrifugation at 450 g for 7 minutes, at room 
temperature.
2.3 Primary T Lymphocyte Purification
It was important to obtain purified T lymphocyte populations with no contaminating 
monocytes or B lymphocytes so two different methods of purifying the PBMC were 
attempted.
2.3.1 Primary T Lymphocyte Purification Using Plastic Adherence
The viability of the PBMC was assessed by Trypan blue exclusion before they were 
resuspended at a cell concentration of 5 x 106 cells/ml, in RPMI 1640 supplemented 
with 10% heat inactivated bovine serum (HIBS). The cells were aliquoted (5 ml) onto 
sterile petri dishes to allow cell adherence to the plastic dish and incubated for one 
hour, after which the non-adherent cells were removed from the dishes using a sterile 
pastette and washing with sterile PBS three times (Bacon et al. 1988). These cells were 
resuspended at 2 x 106 cells/ml in RPMI 1640 supplemented with 10% HIBS in a sterile 
75 cm2 culture flask and incubated for 18 hours, to ensure removal of all adherent cells. 
The non-adherent cells were washed in RPMI 1640 and the cell viability was 
determined again using Trypan blue exclusion. The purified T lymphocytes were 
resuspended at 2 x 106 cells/ml in serum-free RPMI 1640, before assay.
2.3.2 Primary T Lymphocyte Purification Using A Human T Cell Enrichment Column 
Freshly isolated PBMC were prepared as before (2.2) and resuspended in 2 ml IX wash 
buffer provided by column manufacturer. The column was clamped on to a stand and 
the column fluid was allowed to drain into a waste receptacle. The column was then 
equilibrated by washing with 8  ml of IX column wash buffer and the eluate allowed to 
drain into the waste receptacle. A sterile 50 ml tube replaced the waste receptacle and
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the 2 ml cell suspension was applied to the top of the column. This replaced the wash 
buffer contained in the column, which was collected in the sterile centrifuge tube. The 
cells, which were now retained in the column, were incubated at room temperature for 
1 0  minutes.
After this incubation step the cells were eluted from the column with 15 ml of column 
wash buffer. The collected cells were washed in RPMI 1640 and centrifuged at 450 
g for 7 minutes. The supernatant was decanted and the cells resuspended in RPMI 
1640. The cell viability was checked using Trypan blue exclusion and the purified T 
lymphocyte were resuspended at 2 x 106 cells/ml in RPMI 1640 before assay.
2.3.3 Analysis of T Lymphocyte Purity
The primary T cell populations prepared in 2.3.1 and 2.3.2, were analyzed for 
contaminating cells by either examining the populations on cytospins morphologically 
or by FACS analysis. 1 x 10s purified T cells were incubated with 100 yX either mouse 
anti-human CD3 (T lymphocyte marker), or mouse anti-human CD 11 (monocyte 
marker), or mouse anti-human CD 16 (NK cell marker) or mouse anti-human CD 19 (B 
cell marker), (1:50 dilution in RPMI 1640), as primary antibodies, for 30 minutes at 
4°C. The cells were washed with 5 ml sterile PBS and then incubated with 100 yX 
secondary antibody, goat anti - mouse IgG conjugated to phycoerythrin, (1:50 dilution 
in RPMI 1640), for 30 minutes at 4 °C. The cells were washed with 5 ml sterile PBS 
and then analyzed on a Becton Dickinson FACS vantage (excitation wavelength - 488 
nm, emission wavelength - 575 ±  13 nm).
M
2.3.4 Analysis of T Lymphocyte Subsets
The T lymphocyte subsets present in the primary T lymphocyte populations prepared 
in 2.3.1 were identified by a similar method to 2.3.3, although this time the primary 
antibodies used were mouse anti - human CD4, CD8  , CD45RO, CD45RA.
2.4 Human T Lymphoblast Preparation
Human T lymphoblasts were prepared by stimulation of PBMC with 1 /xg/ml 
phytohaemagglutinin (PHA) in RPMI 1640 plus 10% HIBS for 72 h to promote IL-2 
receptor expression. After 72 h, the non - adherent lymphocytes were washed three 
times in RPMI 1640 and maintained in culture with RPMI 1640 plus 10% HIBS 
supplemented with 20 ng/ml human interleukin-2 (IL-2) every 48 hours for 10 - 14 
days. T lymphoblasts were passaged every 2 days by 1:2 dilution in RPMI 1640 plus 
10% HIBS and 20 ng/ml IL-2 (Smith & Cantrell, 1985).
T lymphoblasts were sometimes quiesced into the resting phase of the cell cycle (Go/Gi) 
before use. This involved removing the cells from culture, washing in RPMI 1640 and 
resuspending in RPMI 1640 plus 10% HIBS without IL-2 for approximately 24 hours. 
This ensures that all cells were synchronized into the resting phase of the cell cycle.
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2.5 Maintenance of Cell Lines
The leukaemic Jurkat cell line (J6  subclone) was passaged by 1:10 dilution every three 
days, in RPMI 1640 supplemented with 10% HIBS. These cells were cultured in 175 
cm2 sterile culture flasks and maintained at 37 °C, 5 % C02. The viability of cell lines 
was checked using Trypan blue exclusion before use in all assays.
Chinese hamster ovary cells (CHO) and CHO transfected with B7 (CHO-B7+)(both gifts 
from D.Sansom, BIRD, Bath, U.K.) were maintained in CHO-DMEM (see 2.1.5) in 
175 cm2 culture flasks. The adherent CHO cells were passaged by 1:10 dilution every 
three days. This involved decanting the media and washing the adherent cells with 50 
ml sterile PBS which was then discarded into a waste receptacle. The CHO cells were 
trypsinised with 2 ml Trypsin - EDTA /175 cm2 for 5 minutes at 37 °C, 5 % C02 and 
removed from the flask into 50 ml CHO-DMEM. 2 ml cell suspension was added to 
each new flask and supplemented with 20 ml CHO-DMEM. Alternatively the 
trypsinised cell suspension was used in experimental procedures. If they were to be 
used as antigen presenting cells, the cells required to be fixed as follows : the cell 
suspension was centrifuged at 450 g for 5 minutes and the cells were fixed at a cell 
concentration of 1 - 5 x 106 cells/ml, in 1 ml sterile filtered 0.1 % solution of 
glutaraldehyde in PBS. The cells were fixed in glutaraldehyde for 2 minutes, before 
2 ml of 200 mM glycine (sterile filtered) was added for 2 minutes. 40 ml RPMI 1640 
was added and the cells were centrifuged at 450 g for 5 minutes, before resuspension 
in media at the appropriate cell concentration required for the assay.
2.6 Chemotaxis Assay
Purified T lymphocyte, T lymphoblast and the Jurkat T cell line migration after 
stimulation with certain chemoattractants was examined using a 48-well 
microchemotaxis chamber (Neuro Probe)(Cabin John, MD, USA).
The chamber was oriented so that the trademark was always kept in the upper left 
comer. The lower wells were filled with either 25 /xl chemoattractant in RPMI 1640 
that had been warmed to 37 °C or warmed RPMI 1640 only, as a vehicle control. 1 
mm of the comer of a polyvinylpyrrolidine (PVP) free polycarbonate filter (8 /xm pore 
size) membrane was cut off, enabling easier identification of the orientation of the 
membrane (Bacon et al. 1988). The filter was lifted carefully and placed carefully over 
the lower wells with the cut comer kept in the upper left comer. The silicone gasket 
was applied with the cut comer at the upper left, then the top plate with the trademark 
also oriented at the upper left. The top plate was tightened on with the screws then the 
upper wells were covered with a glass microscope slide, to stop evaporation of the 
chemoattractant while the chamber was allowed to equilibrate (5% CQ2, 30 minutes, 
37°C). 50 fd of cell suspension in RPMI 1640 at 2 x 10s cells/ml was placed in each 
of the upper wells, making sure that no air bubbles were trapped in the wells. The 
upper wells were again covered with the glass microscope slide and left at 5% C02, 37 
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. 2.1 Schematic Diagram of the 48-Well Microchemotaxis Assay - transverse 
cross-section
After incubation, the screws were removed and the whole chamber was inverted onto 
a paper towel. The bottom plate was detached carefully from the upper plate and the 
silicone gasket. The inversion of the whole chamber meant that the cells that had 
migrated, and had therefore moved through the pores of the membrane, were now on 
the surface of the membrane which was now uppermost. The filter was removed and 
the non-cell side (the underneath side) was thoroughly washed three times in sterile 
PBS. The filter was allowed to dry then fixed in methanol for 2 minutes and stained 
with Diff-Quik. The wet membrane was placed on a microscope slide, allowed to dry 
and lymphocyte migration was assessed by counting the number of cells attached to the 
lower surface of the filter membrane, in five high power (400 x) magnification fields 
for each well.
2.7 Polarisation Assay
Before T lymphocytes migrate in response to a chemoattractant the cells undergo 
several changes after activation including a change in morphology from spherical T 
lymphocytes to a more polarised shape.
The polarising response of purified T lymphocytes to chemoattractant was analysed by 
detecting morphology changes in the cells (Haston & Shields, 1985; Newman & 
Wilkinson, 1993). 3 x 106 purified T lymphocytes were washed three times with sterile 
Hank’s Balanced Salt Solution containing 10 mM morpholinopropane sulphonic acid 
(pH 7.4)(HBSS/MOPS) and resuspended in 1.5 ml HBSS/MOPS in 6  ml polystyrene 
tubes. The cells were then incubated with chemoattractant or vehicle control at 5 % 
C02, 37 °C. The incubation times were varied to find an optimal incubation time (30 -
240 minutes).
The reaction was stopped by the addition of 1.5 ml 2.5 % glutaraldehyde in sterile PBS 
for 15 minutes and the cells were washed in HBSS/MOPS three times. The samples 
were then resuspended in 0.5 ml HBSS/MOPS. The extent of polarisation was assayed 
by counting the number of polarised cells compared to cells with a spherical shape in 
a total count of 300 purified T lymphocytes, under 400 x magnification for each 
sample.
2.8 Actin Polymerisation Assay
Another change that occurs after T lymphocytes are activated by a chemoattractant is 
a change in the actin structure in the cytoskeleton of the cells. T lymphocytes in the 
resting state have globular actin (G - actin). When they are activated this G - actin 
polymerises to filamentous actin (F - actin). This can be detected using FITC - 
phalloidin which will only bind to the F - actin, not G - actin, and as it is fluorescent 
this can be detected using FACS analysis.
0.5 ml purified T lymphocytes at 2 x 106 cells/ml in RPMI 1640 were stimulated with 
chemoattractant or vehicle control (10 /xl) in a 24 well plate, 5 % C 02, 37 °C. The 
reaction was quenched by removing the cell suspension from the plate with a pastette 
into FACS tubes containing 0.5 ml of 7.4 % formaldehyde in PBS solution. The cells 
were left for 10 minutes at room temperature to fix. Excess PBS was added and the 
cells were spun for 7 minutes at 500 g. The pellet was resuspended in 100 /xl of 1 % 
formaldehyde in PBS solution supplemented with 1 % HIBS. 100 /xl of 0.3 /xM FITC -
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phalloidin in 0.1 % triton/ PBS was added to the cell suspension and the cells were left 
to incubate at 4 °C for 30 minutes. The cells were then washed twice in PBS and 
resuspended in 500 pi of 1 % formaldehyde in PBS solution supplemented with 1 % 
HIBS. The samples were stored in the dark at 4 °C until analyzed. They were 
analyzed on a Becton - Dickinson FACS vantage, excitation wavelength - 488 nm, 
emission - 530 ±  15 nm (Personal communication with Dr S. Kellie, Yamanouchi, 
U.K.).
2.9 Determination of Cytosolic Free Calcium rCa2+lj
Changes in [Ca2+]j in human T lymphoblasts, the Jurkat cell line and purified T 
lymphocytes was measured by monitoring the fluorescence of these cells loaded with 
the calcium indicator, fura-2 acetoxymethyl ester (fura-2). This compound is lipophilic 
so can penetrate the cell membrane and pass into the cell interior where the ester groups 
are cleaved trapping the indicator in the cell cytosol. Fura-2 undergoes a spectral shift 
upon binding Ca2+ and by using the ratio of fluorescence intensities at two separate 
excitation wavelengths, as opposed to only using one excitation wavelength, differences 
between loading with the dye on different days is taken into account, and we can 
calculate the [Ca2+]i and compare [Ca2+]j elevations from different experiments.
The cells were resuspended at 107 cells/ml in RPMI 1640 supplemented with 10% HIBS 
in 50 ml sterile tube. The cells were incubated with 2.5 pM fura-2 acetoxymethyl ester 
for 30 minutes, 37 °C, in the dark (Ward et al. 1988). The cells were washed three 
times in 50 ml of HBSS/BSA (pH 7.4, 0.25 % bovine serum albumin) and finally 
resuspended at 2 x 106 cells/ml in HBSS/BSA. The cell suspension was kept in the
dark at all times.
Aliquots (2 ml) were dispensed into a quartz cuvette and the external calcium 
concentration adjusted to 1 mM with CaCl2. The [Ca2*]j was determined by recording 
the fluorescence signals of these stirred aliquots at 37° C in a fluorimeter (slit widths - 
4 nm), with dual excitation wavelengths (340 nm and 380 nm) and a single emission 
wavelength of 510 nm before and after appropriate stimuli.
Cells were lysed with 125 fiM digitonin (added from a 4 mg/ml digitonin stock made
up in 70% ethanol) to give the maximum fluorescence signal (R ). The fluorescence
level in Ca2+ free medium ( R J  was calculated by adjusting the pH of the cell lysate 
to > 8.5 with NaOH (40 fd of 4M NaOH solution) and then adding 10 mM EDTA to 
reduce the extracellular free concentration to < 10 nM. R ^  and R ^  were then used 
in the ratio method with PIT software (Grynkiewicz et al. 1985). In brief, conversion 
of the sample fluorescence ratio (R) to intracellular free calcium levels ([Ca2+]j) were 
made using a simple formula, where R is the sample fluorescence ratio in arbitrary 
units and Kd is the dissociation constant of the Ca2+ - fura-2 complex which is 224 nM 
(Grynkiewicz et al. 1985) :
[Ca2+L = (R - R,nin/ Rmu - R) * Kj
Fura-2 loaded cells were allowed to equilibrate for 2 minutes at 37 °C before drugs or 
vehicles were added directly to the cuvette containing the cells. The quartz cuvette was 
washed thoroughly between each sample.
2.10 Phosphoinositide 3-kinase Activity
One signal pathway relevant to chemotaxis may be the putative pathway regulated by 
phosphoinositide 3-kinase (PI 3-kinase) and its metabolic products, D-3 
phosphoinositide lipids. One approach is to examine the production of the D-3 
phosphoinositides in this enzymatic pathway. Cells are radiolabelled with f 2P]- 
orthophosphate and stimulated with appropriate stimuli. The phosphoinositides are then 
extracted and analysed using High Performance Liquid Chromatography. Alternatively, 
PI 3-kinase activity can be determined, after stimulation, by immunoprecipitating the 
enzyme with anti - human PI 3-kinase coupled to Affigel beads, and then performing 
an in vitro lipid kinase assay with an exogenous substrate and [?-32P] labelled ATP, on 
the immunoprecipitates. The resulting radiolabelled phosphoinositides are then 
visualised using thin layer chromatography.
2.10.1 In Vitro Measurements of Phosphatidvlinositol Lipid Metabolism 
Purified T lymphocytes, Jurkat cells or T lymphoblasts were washed three times in 
phosphate free (Dulbecco’s Modified Eagle’s Medium (DMEM) containing 20 mM 
HEPES, pH 7.2), with a 10 minute incubation at 37°C, between each wash. Cells 
were resuspended in 5 ml phosphate free DMEM , 20 mM HEPES and 10 % dialysed 
HIBS (dialysed against saline).
After incubation with 1 mCi of [32P] labelled orthophosphate (32Pi) for 4 hours at 37°C, 
the cells were washed three times in phosphate free DMEM and resuspended in RPMI 
1640. 0.5 ml aliquots were dispensed into eppendorf tubes and treated with appropriate 
stimuli at 37°C. The reactions were quenched with 0.5 ml
chloroform/methanol/distilled H20 (32.65%/65.3%/2.15%(v/v)) and maintained on ice 
for 10 minutes (Jackson et al. 1992). Phases were separated by addition of 200 /xl 
chloroform (containing 20 /xg Folch lipids) and 200 /xl 2.4M HC1, 5 mM 
tetrabutylammmonium sulphate. The samples were vortexed and centrifuged (16000 
g, 5 minutes, 4°C). The lower phase was removed carefully into clean eppendorf tubes 
containing 0.5 ml synthetic upper phase (0.1 M HC1, 5 mM tetrabutylammonium 
sulphate, 25 mM EDTA). The phases were again mixed by vortexing and centrifuged 
(16000 g, 5 minutes, 4°C) and the lower phase removed into clean tubes then dried in 
vacuo (Savant speedvac).
The samples were then deacylated by adding 1 ml 25% w/v methylamine in water/ 
methanol/butanol (44.4%/44.4%/ll.l%). Samples were vortexed, incubated (40 
minutes, 53°C) and subsequently cooled on ice for 5 minutes and dried in vacuo. 0.5 
ml sterile water was added to the dried samples, followed by 0.6 ml n-butanol/40-60% 
petroleum ether/acetate (80%/16%/4% v/v). After vortexing and centrifuging (16000 
g, 30 seconds, 23°C) the upper phase was discarded and the lower phase dried in 
vacuo.
The resulting pellets were resuspended in 120 /xl sterile water in a sonicating bath. The 
deacylated lipids were separated by high performance liquid chromatography (HPLC) 
on a partisphere-SAX column using a gradient based on buffers A (ddH20)/B [1.25 M 
(NH^HPOJ](pH 3.8) at a flow rate of 1.0 ml/minute: 0 minute, 0 % B; 5 minutes , 
0 % B; 45 minutes, 12 % B; 60 minutes, 30 % B; 61 minutes, 100 % B; 65 minutes, 
100 % B; 6 6  minutes, 0 % B (Ward et al. 1992a). The eluate was fed into a Canberra 
Packard A-500 Flo-One on-line fote-radiodetector where it was mixed with three parts
Flo-Scint IV scintillation cocktail and the results analyzed on the Flo-one data program 
(Radiomatic, USA).
2.10.2 Preparation of Protein A Affipel Beads
500 /xl 50 % suspension of Protein A Affigel beads in PBS was placed in a clean 
eppendorf tube and washed three times in PBS. After the third wash all the PBS was 
removed with a Hamilton syringe. 25 /xl rabbit polyclonal anti-human PI 3-kinase was 
added to the beads and 1 ml PBS added, to fill the eppendorf tube. The tube was then 
rotated at room temperature for 2 hours. Finally, the antibody coupled beads were 
washed three times with PBS and resuspended in PBS to 500 /xl to give a 50 % 
suspension. The beads were stored at 4 °C until ready to be used.
2.10.3 Immunoprecipitation of PI 3-Kinase
The purified T lymphocytes were resuspended at 4 x 106 cells/ml in RPMI 1640. 1 ml 
cell suspension was stimulated with appropriate treatment. The cells were spun down 
into pellets (450 g, 7 minutes). 50 ml IX NP40 lysis buffer (see 2.1.5) was 
supplemented with 46 mM B-glycerophosphate, 1 /xg/ml leupeptin, 1 /xg/ml 
chymostatin, 1 /xg/ml antipain, and 1 /xg/ml pepstatin A before use and the lysis buffer 
was kept on ice (Ward et al. 1992b). The cells were resuspended in 1 ml ice cold IX 
NP40 lysis buffer and transferred to eppendorf tubes containing 10 /xl 
phenylmethylsulfonyl fluoride (PMSF). These eppendorf tubes were placed in a rotator 
and left to rotate for 15 minutes at 4 °C.
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The lysates were then precleared, to reduce non-specific binding of the beads to the cell 
lysates. The cell lysates were removed to clean eppendorf tubes containing 40 /xl 
uncoupled protein A bead solution and rotated for 1 hour at 4 °C, after which time the 
beads were spun down (450 g, 10 minutes) and the uncoupled lysates were again 
removed to clean eppendorf tubes, this time containing 20 /xl rabbit anti-human PI 3- 
kinase coupled to Protein A bead solution. The lysates were left to rotate for 2 hours 
at 4 °C. Then the coupled beads were pelleted at 450 g for 10 minutes. 20 /xl cell 
lysate was kept as a control in a separate clean eppendorf tube and the anti - PI 3-kinase 
beads now coupled to the PI 3-kinase enzyme were then used in a kinase assay.
2.10.4 In Vitro Lipid Kinase Assay
The immunoprecipitates, from 2.10.3, were washed thoroughly. Three washes in 1 ml 
IX NP40 lysis buffer, single washes in 1 ml PBS, 1 ml LiCl (0.5 M in H20), and 1 ml 
H20 . Between each wash the beads were pelleted at 450 g for 10 minutes and all the 
wash buffer, except for 100 /xl containing the beads, was removed by aspiration . After 
the last H20  wash the beads were transferred to clean eppendorf tubes. The final wash 
was with 1 ml lipid kinase buffer (see 2.1.5). After pelleting, this wash buffer was 
removed completely with a Hamilton syringe and the pellet was resuspended in 80 /xl 
lipid kinase buffer, 1 0 0  /xl substrate (1  mg phosphatidylinositol and 1 mg 
phosphatidylserine in 1 ml 25 mM HEPES/1 mM EDTA, sonicated into solution) 
(Ward et al. 1992b). The assay was initiated by adding 20 /xl [7 -32P]ATP/cold ATP 
(200 /xl lipid kinase buffer, 7 /xl [7 -32P]ATP, 2 /xl 100 mM cold ATP in 100 mM Tris 
pH 7.0) to each eppendorf tube including the control eppendorf tube, and then leaving 
the tubes at room temperature for 15 minutes. The reaction was quenched with 200 /xl
IN HC1 and 400 fd chloroform:methanol (1:1), then the eppendorf tubes were spun at 
16000 g for 30 seconds. This separated the phases and the lower organic phase 
containing the lipids was removed with a gel loading tip into clean eppendorf tubes. 
This phase was washed with 1 ml 1:1 methanol/HCl and the organic phases separated 
again by centrifugation at 16000 g for 2 minutes. The lower phase was then removed 
and dried in vacuo.
When the samples were dry they were resuspended in 50 fd chloroform. The samples 
were then spotted onto a potassium oxalate (1  %) sprayed thin layer chromatography 
plate, 10 fd at a time, drying between each spot. Phospholipid standards, e.g., Ptdlns, 
PtdIns(4)P and PtdIns(4,5)P2, were also added. Each lane was clearly labelled, then 
the plate was placed in an equilibrated thin layer chromatography (TLC) tank containing 
130 ml propan-l-ol, 6 6  mis H20  and 4 mis glacial acetic acid with a piece of 3M paper 
as a support for the solvent. The TLC plate was allowed to stand upright in the tank 
overnight.
The plate was removed from the tank and allowed to dry in a fume hood, then placed 
in an iodine tank to visualise the phospholipid substrates and standards. When the plate 
was dry again it was exposed to film using intensifying screens and left at - 80 °C until 
ready to develop.
2.10.5 Wortmannin Inhibition
Wortmannin, the PI 3-kinase inhibitor was used in many of the assays to assess the 
involvement of PI 3-kinase. Purified T lymphocytes were incubated with the 
wortmannin solutions or vehicle control for 10 minutes, 5 % C 02, 37 °C. The cells 
were then stimulated with chemoattractant and the assays performed as normal. The 
final concentration of ethyl acetate was less than or equal to 0.005 %. Control 
migration experiments were performed with ethyl acetate only, at concentrations 
equivalent to the ethyl acetate concentrations present in the appropriate wortmannin 
solutions.
2.11 Proliferation Assay
The ability of lymphocytes to proliferate is a useful measure of lymphocyte function. 
Proliferation can be measured by the incorporation of [3H]-thymidine into T 
lymphocyte DNA. The purified T lymphocytes were resuspended in RPMI 1640 plus 
10% HIBS at 2.5 x 10s cells/ml. 190 /xl T lymphocyte suspension was aliquoted into 
the wells of a 96-well, flat bottomed microtitre plate. Quadruplicate aliquots were 
treated with 10 /xl vehicle, UCHT1, fixed CHO-B7+, RANTES, mouse monoclonal 
anti-human RANTES, or various combinations of these stimuli. Each treatment was 
optimised using a range of concentrations.
The cells were then incubated for 72 hours at 37 °C, 5 % C02. The cells were pulsed 
with 0.5 /xCi/well pH] thymidine for the final 18 hours of culture. The cells were then 
harvested onto Whatman GF/A filters using a multiple automated cell harvester. The 
incorporation of pH]-thymidine was measured using standard liquid scintillation
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counting techniques. The radioactivity collected on the filter paper was assayed by 
placing it in 4 mis of scintillation fluid (Optiphase) and counted on a fl-scintillation 
counter (LKB). Results are expressed as counts per minute (cpm).
2.12 RANTES Production and Quantitation
The production of RANTES by purified T lymphocytes stimulated with various 
treatments can be measured using a double ligand sandwich Enzyme-Linked- 
Immunosorbent-Assay.
490 /xl purified human T lymphocytes at 2 x 10s cells/ml in RPMI 1640 supplemented 
with 10 % HIBS were aliquoted into multiwell culture plates and incubated at 37 °C, 
5 % C02. UCHT1, CHO-B7+ and vehicle additions were made at 10 /xl to give a final 
volume of 500 /xl and incubated at 37 °C, 5 % CQ for 0 - 9 6  hours. After incubation, 
the cells were pelleted (450 g, 7 minutes) and the cell free supernatants were removed 
by suction, sub-aliquoted and stored frozen at - 20 °C.
A 96 well culture plate was coated with mouse monoclonal anti-human RANTES, 50 
/xl/well overnight at 4 °C at a final concentration of 1 /xg/ml in coating buffer (25 mM 
Na2C03, 30 mM NaHC03 in distilled water, pH 9.6). The plate was washed three 
times with buffer (PBS/0.05 % Tween 20, pH 7.5) to remove any unbound antibody. 
Diluted standards (6 , 4, 3, 2, 1, 0.5, 0.25, 0.125, 0.63 ng/ml) and samples in wash 
buffer plus 2 % HIBS were loaded in duplicate, 50 /xl/well. The first four wells were 
loaded with buffer only. The covered plate was incubated at 37 °C for 2 hours.
Goat polyclonal anti-human RANTES was biotinylated by dissolving RANTES in 100 
mM HEPES, pH 8.5, at a concentration of 2 mg/ml. 10 /xl of 20 mg/ml biotin (long 
arm) N hydroxysuccinimide ester (BNHS) in N,N-dimethylformamide (DMF) was 
added. With occasional stirring, the peptide was incubated at room temperature for 2 
hours. The reaction was stopped by adding 10 /xl triethanoloamine. The biotinylated 
protein was then dialysed against three changes of 2 litres of PBS.
The plate was washed three times in wash buffer and 50 /xl of 1 /xg/ml biotinylated goat 
anti-human RANTES in wash buffer plus 2 % HIBS was added to each well and 
incubated for 1 hour at 37 °C. The unbound biotinylated antibody was removed by 
washing three times in wash buffer. The enzyme streptavidin peroxidase was then 
added, 50 /xl/well at 0.5 /xg/ml in wash buffer. The plate was covered and incubated 
at 37 °C for 30 minutes. The plate was then washed three times in wash buffer. The 
substrate used was 1,2 phenylene dihydrochloride (OPD). This is oxidised to produce 
a coloured end product. 100 /xl substrate was added to each well. The plate was 
allowed to incubate in the dark at room temperature for 25 minutes. After which the 
reaction was quenched by adding 150 /xl stop solution (50 mM H2S04).
The amount of bound conjugate can be calculated as this is proportional to the intensity 
of colour in each well, and therefore equivalent to the amount of RANTES present. The 
colour intensity was calculated using a microtitration plate reader at a wavelength of 
490 nm. An average optical density (O.D.49Q) was calculated for each set of duplicate 
samples. The average of the blank wells was then subtracted from the average optical 
density to give a net O.D.490. Standard curves were plotted using Curve fit/cubic spline 
















Fig. 2.2 Representative Standard Curve for RANTES ELISA 
A representative standard curve for the detection of known concentrations of the 
RANTES peptide (6 - 0.63 ng/ml) by a double ligand sandwich ELISA. The average 
optical density (O.D.490) was calculated for each set of duplicate wells and the net
O.D.490 was calculated by subtracting the average of the blank wells. The RANTES 
content of each test sample was then calculated from this standard curve.
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2.13 Analysis of CD25 Expression
Another useful measure of lymphocyte function and activation is to monitor the 
expression of the IL-2 receptor complex (IL-2R) on the T lymphocytes after 
stimulation. The IL-2R is a multimeric structure of three polypeptides, a 55 kDa a- 
chain, a 75 kDa 15-chain and a 64 kDa 7 -chain which associate to form a high affinity 
IL-2R. We analysed the expression of the 55 kDa a-chain which is recognised by 
mouse anti-human CD25 antibody.
Primary T lymphocytes were purified from PBMCs using a R+D enrichment column, 
as described in 2.3.2. The purified T lymphocytes were resuspended at 2 x 10s cells/ml 
in RPMI 1640 supplemented with 10 % HIBS. 470 /xl T lymphocyte suspension was 
aliquoted into the wells of a 24-well, flat bottomed microtitre plate. The wells were 
treated with 10 /xl vehicle, UCHT1, fixed CHO-B7+, RANTES, or a combination, and 
made up to a final volume of 500 /xl with vehicle. The cells were then incubated for 
48 hours at 37 °C, 5 % C02.
After incubation the cells were washed twice in RPMI 1640 before incubation with 
either the mouse anti-human CD25 (anti-IL-2 receptor)(l:50 dilution in RPMI 1640) 
which was conjugated to FITC, or a control IgG antibody conjugated to FITC to check 
for non-specific binding, for 30 minutes at 4°C. The cells were then washed with 
sterile PBS twice and then analyzed on a Becton Dickinson FACS vantage (excitation 
wavelength - 488 nm, emission wavelength - 530 ±  15 nm).
2.14 IL-2 Production and Quantitation
The production of IL-2 by purified T lymphocytes stimulated with various treatments 
can be measured using the CTLL cell line which are IL-2 dependent (Ward & Cantrell, 
1989; Rayter et al. 1992).
Primary T lymphocytes were purified from PBMCs using a R4-D enrichment column. 
The purified T lymphocytes were resuspended at 2 x 106 cells/ml in RPMI 1640 
supplemented with 10 % HIBS. 470 /xl T lymphocyte suspension was aliquoted into the 
wells of a 24-well, flat bottomed microtitre plate. The wells were treated with 10 /xl 
vehicle, UCHT1, fixed CHO-B7+, RANTES, or a combination and the final volume 
made up to 500 /xl with vehicle. The cells were then incubated for 24 hours at 37 °C, 
5 % C02. After incubation, the cells were pelleted (450 g, 7 minutes) and the cell free 
supernatants were removed by suction, sub-aliquoted and stored frozen at - 20 °C.
The CTLL assay was carried out by Dr. J. McLeod. In summary, CTLL cells which 
had been fed with rIL-2 36 hours previously were used for the IL-2 assays. These cells 
were washed, then incubated in complete medium without rIL-2 for at least 1 hour. 
100 /xl of diluted rIL-2 standards (0.019 - 20 I.U./ml) were aliquoted into 96 well 
microtitre culture plates. 1 0 0  /xl of assay supernatants were added to the test wells. 
100 /xl containing 5 x 104 CTLL cells were added to each well. The cells were 
incubated with the supernatants for 24 hours (37 °C, 5 % CO2). 0.5 /xCI [3H] - 
thymidine was added to each well. The cells were then incubated for another 4 hours, 
harvested onto Whatman GF/A filters using a multiple automated cell harvester.
The incorporation of pH]-thymidine was measured using standard liquid scintillation
counting techniques. The radioactivity collected on the filter paper was assayed by 
placing it in 4 mis of scintillation fluid (Optiphase) and counted on a B-scintillation 
counter (LKB) and expressed as cpm (Laughton et al. 1994).
An average cpm reading (±  SEM) was calculated for each set of triplicate standards. 
Standard curves were plotted using a logistic (Fig. 2.3). The IL-2 content of each test 










Fig. 2.3 Representative Standard Curve for IL-2 Quantitation 
A representative standard curve for the detection of known concentrations of the IL-2 
peptide (0.008 - 8.210 ng/ml) by a CTLL cell line assay. The IL-2 content of each test 
sample was then calculated from this standard curve.
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Statistical Analysis
The results in the text, figures and tables of this thesis are presented as the mean ±  
standard error of the mean (SEM) of Hn" experiments unless otherwise stated. 
Statistical significance was evaluated using the Student’s t-test (paired or unpaired) or 
where appropriate, effects of treatment compared to control were analyzed by two-way 




3.1 Induction of Migration of T Lymphocytes by RANTES
3.1.1 Purity of Primary T Lymphocyte Preparations
Primary T lymphocytes purified from PBMCs by plastic adherence and using a R+D 
enrichment column were stained with antibodies raised against CD3 (T cell marker), 
CD 14 (monocytic cell marker), CD 16 (NK cell marker), CD 19 (B cell marker) (Table
3.1 and Table 3.2). The purification methods were satisfactory producing a relatively 
pure T lymphocyte population with very few contaminating cells. Purification by 
plastic adherence or using the R+D column produced a 84.2 +  1.65 % CD3+ 
population and 84.78 ±  4.12 % CD3+ population, respectively (n =  5). The two 
methods of purification did not significantly affect the purity of the populations obtained 
when compared using a unpaired Student’s t-test (p > 0.05).
Table 3.1 Extent of Purification of T Lymphocytes from PBMCs Using Plastic Adherence
Donor control
antibody
CD3+ CD14+ CD16+ CD19+
A 0 . 1 1 84.1 2.3 0 . 6 0.5
B 0.08 83.3 1.9 2.34 3.8
C 0 . 0 2 90.1 4.1 1 .1 2 .1
D 0 . 1 2 79.9 0 . 8 0.4 0 . 6
E 0 . 2 1 83.6 2.4 0.5 2 .1
T lymphocyte enriched populations were purified from PBMCs, using plastic adherence. The % cells positive for antibodies raised against 
CD3, CD14, CD16, and CD19 were examined using a FACS based assay.
Table 3.2 Extent of Purification of T Lymphocytes from PBMCs Using A R+D Enrichment Column
Donor control
antibody
CD3+ CD14+ CD16+ CD19+
F 0 . 2 1 68.9 1 .8 1.5 1 .2
G 0.18 89.6 2.3 1.5 1.9
H 0.26 85.6 1.4 0.9
i
0 . 8
I 0.05 92.4 3.1 0.3 0 . 2
J 0 . 1 1 87.4 2 . 2 1.9 2 . 0
T lymphocyte enriched populations were purified from PBMCs, using a R+D enrichment column. The % cells positive for antibodies raised 
against CD3, CD 14, CD 16, and CD 19 were examined using a FACS based assay.
3.1.2 Effect of RANTES on the Migration of Primary T lymphocytes 
RANTES (0.1 -100 ng/ml) stimulates locomotion of T lymphocytes, purified by plastic 
adherence. Peak chemotactic effects were produced with 1 or 10 ng/ml RANTES, 
depending on donor (Fig. 3.1). Low concentrations (0.1 ng/ml) of RANTES and high 
concentrations (100 ng/ml) did not increase migration of the T lymphocytes above 
vehicle control levels producing a "bell-shape-like" concentration dependent response 
curve. The actual number of cells migrating was largely dependent upon the cell 
preparations used, with T lymphocyte populations from different donors having a 
marked difference in response to the chemokine. Peak chemotactic effects with 1 ng/ml 
ranged from 40 ±  19.2 to 130 ±  32.4 cells migrating in 5 high power fields (n = 6 ).
Time course experiments were also carried out on the primary T lymphocytes, purified 
by plastic adherence, and their chemotactic response to 1 and 10 ng/ml RANTES. The 
locomotion was incubation time dependent (Fig. 3.2). A "bell-shape-like" time course 
response curve was produced and an incubation time of 4 hours was found to be 
optimal.
Checkerboard analysis was used to distinguish whether RANTES-induced migration is 
chemotactic or chemokinetic (Table 3.3). Chemokinesis is the increase of migration 
of random turning cells and will occur when there is no concentration gradient present,
i.e. when there are equal concentrations of chemoattractant in the upper and lower 
wells. Chemotaxis, however, is the vectorial migration of cells along a concentration 
gradient. Migration of primary T lymphocytes was induced significantly, with higher 
concentrations of RANTES in the lower wells. There was little migration when the 
concentration of RANTES in the upper and lower wells was equal. Hence, the primary
T lymphocyte response to RANTES is a chemotactic response rather than the result of 
an increase in random migration.
Table 3.3 Checkerboard Analysis of RANTES-Induced Migration of Primary T 
Lymphocytes
cells migrating in five high power fields
upper well-* 
lower well 4
0  ng/ml 0 . 1  ng/ml 1 0  ng/ml 1 0 0 0  ng/ml
0  ng/ml 9 ( ± 1 .0 ) 21.6 (±6.5) 18.5 (±6.9) 5 (±2.0)
0 . 1  ng/ml 31 (±15.8) 16.3 (±11.3) 32.3 (±14.5) 14.5 (±0.5)
1 0  ng/ml 93.3 (±9.2) 60.3 (±5.3) 28.6 (±7.5) 27 (±5.0)
1 0 0 0  ng/ml 24.6 (±10.5) 54.6 (±8.9) 36.3 (± 6 .8 ) 32 (±8.3)
Purified T lymphocytes were assayed for migration in response to RANTES, with the 
indicated concentration of RANTES (0.1 - 1000 ng/ml) in the upper and lower wells, 
shown above and to the left of the matrix, respectively. Each value is mean (±  SEM) 
of triplicate or quadruplicate wells in a single representative experiment.
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3.1.3 Effect of RANTES on Migration of Jurkat T Cells
RANTES (0.1 - 100 ng/ml) failed to cause migration of Jurkat T cells above vehicle 
control levels (Fig. 3.3 a)). The incubation time with RANTES was not a factor as 
incubation with 1 ng/ml or 10 ng/ml RANTES over a time course of 1 - 5 hours did 
not lead to increased migration of the Jurkat T cells above vehicle control levels (Fig.
3.3 b)).
Several microchemotaxis chamber polycarbonate membranes were used with pore sizes 
of 5, 8 , and 12 \lm pore size but RANTES-induced migration was still not observed 
above basal levels (n = 2 , for each pore size).
3.1.4 Effect of RANTES on Migration of Primary T Lymphocytes Purified from Blood 
Packs
T lymphocytes that had been purified from whole blood packs by plastic adherence, 
obtained from the Blood Transfusion Service, were also used in chemotaxis 
experiments. RANTES (0.1 - 100 ng/ml) did not induce migration of these T 
lymphocytes (Fig. 3.4 a)). Altering the incubation time with RANTES, over a time 
course of 1 - 5 hours, did not cause induction of migration either (Fig. 3.4 b)). The 
T lymphocytes were purified from 4 day old blood that had been donated to the Blood 
Transfusion Service.
3.1.5 Effect of RANTES on Migration of Quiescent T Lymphoblasts
RANTES (0.1 - 100 ng/ml) did not induce a chemotactic response in quiescent T 
lymphoblasts, 10 -14  days old, above that of vehicle control levels (Fig. 3.5 a)). The 
incubation time with RANTES was not a factor as incubation with 1 ng/ml or 10 ng/ml 
RANTES over a time course of 1 - 5 hours did not lead to increased migration of the 
quiescent T lymphoblasts above vehicle control levels (Fig. 3.5 b)). Different 
polycarbonate membrane with varying pore sizes (5 -10  /xm) were used in the 48-well 
microchemotaxis chamber but RANTES still did not induce migration of the quiescent 
T lymphoblasts.
3.1.6 Effect of RANTES on Migration of T Lymphoblasts
The effect of RANTES on in vitro migration of T lymphoblasts was assessed at several 
stages in their preparation from PBMC : after stimulation with PHA for 3 days (Fig.
3.6 a)), after stimulation with PHA for 3 days followed by incubation with IL-2 for 48 
hours (Fig. 3.6 b)), after stimulation with PHA for 3 days followed by incubation with 
IL-2 for 4 days (Fig. 3.6 c)), after stimulation with PHA for 3 days followed by 
incubation with IL-2 for 10 days (Fig. 3.6 d)). RANTES (0.1 - 100 ng/ml) did not 
induce migration of any of the cell preparations after incubation for 4 hours in a 48-well 
microchemotaxis chamber above the levels of migration seen with vehicle control only.
3.1.7 Comparison of RANTES Induced Migration in Primary T Lymphocytes Purified 
by Two Different Methods
Primary T lymphocyte were purified from the same blood donations by plastic 
adherence and using the R+D T cell enrichment column. The cells were then 
incubated with RANTES (0.1 - 100 ng/ml) in a microchemotaxis assay for 4 hours (n 
=  5)(Fig. 3.7). The different methods of purification did not alter RANTES-induced 
migration.
3.1.8 Induction of Polarisation of T Lymphocytes by RANTES
RANTES induced polarisation of T lymphocytes, recognised by a change in shape from 
spherical lymphocytes to a polarised, elongated form (Fig. 3.8). RANTES (0.1 - 1000 
ng/ml) induced an increase in polarisation of primary T lymphocytes, purified by plastic 
adherence. A "bell-shape-like" concentration dependent response curve was produced 
and peak polarisation was achieved in response to 1 to 10 ng/ml RANTES (Fig. 3.9). 
Although the absolute number of cells that responded to RANTES was dependent upon 
the donor used, the fold increase in polarised cells compared with vehicle-treated cells 
was consistent for each RANTES concentration tested. For example, cells polarised 
with RANTES (10 ng/ml) induced a significant increase in polarisation (p < 0.01, two 
way analysis of variance), with a 4.56 ±  0.42 - fold increase in percentage of cells 
polarised, compared with vehicle-treated cells (n = 5)(Table 3.4).
RANTES-induced polarisation of primary T lymphocytes was time dependent. 
Experiments with cells treated with 1 ng/ml RANTES over a time course of 30 - 240 
minutes showed that RANTES polarisation had optimal effects within 60 minutes (Fig. 
3.10).
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Table 3.4 Polarisation in Response to RANTES
Donor % cells polarised in response 
to vehicle
% cells polarised in response 
to 10 ng/ml RANTES
fold increase in 
polarisation
1 1 .2  ±  0 . 8 5.3 ±  1.6 4.41
2 6 .1  ±  2 . 6 27.2 ±  4.2 4.46
3 4.2 ±  0.6 16.1 ±  2 .1 3.83
4 3.4 ±  1.2 12.9 ±  2.9 3.79
5 2.8 ±  0.3 13.1 ±  3.1 4.68
T lymphocytes were purified using plastic adherence then incubated with vehicle control or 10 ng/ml RANTES for 1 hour. 
After that time the extent of polarisation was assessed.
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3.1.9 Comparison of RANTES Induced Polarisation in Primary T Lymphocytes Purified 
By Two Different Methods 
Primary T lymphocyte were purified from the same blood donations by plastic 
adherence and using the R+D  T cell enrichment column. The cells were then 
incubated with RANTES (0.1 - 100 ng/ml) for 1 hour (n = 5)(Fig. 3.11). The extent 
of polarisation induced by RANTES in the cells purified by the different methods was 
compared. RANTES-induced polarisation was not affected by the purification method 
used.
In addition, polarisation assays were performed on different primary T lymphocyte 
populations and the extent of RANTES (1 ng/ml) induction of polarisation was 
examined. In addition, the T cell subsets present in these populations were examined 
using antibodies against CD4, CD8 , CD45RO and CD45RA cell surface antigens. The 
extent of RANTES (1 ng/ml) induction of polarisation in the different populations was 
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Table 3.5 Surface Expression of T Lymphocyte Subset Markers
Donor control
antibody
CD3+ CD4+ CD8 + CD45RA+ CD45RO+
_
% cells polarised in 
response to RANTES
6 0.24 86.3 37.7 33.7 29.1 48.9 15.43
7 0.34 91.6 43.2 39.8 21.3 31.6 10.78
8 0 . 0 2 92.1 37.3 42.5 61.0 73.4 8.95
9 0.18 79.4 38.8 36.4 35.4 61.2 13.65
1 0 0 . 6 8 82.3 39.4 40.8 29.9 34.5 14.2
T lymphocytes were purified using plastic adherence then the % cells positive for antibodies raised against CD3, CD4, CD8 , CD45RA, 
CD45RO were examined using a FACS based assay. Each cell preparation was also incubated for 1 hour with 1 ng/ml RANTES and after 
that time the extent of polarisation was assessed.
3.1.10 Induction of Actin Polymerisation in T Lymphocytes by RANTES 
RANTES (0.1 - 100 ng/ml) induces actin polymerisation from G-actin to F-actin in 
primary T lymphocytes. A "bell-shape-like" concentration dependent response curve 
is observed, with 10 ng/ml causing peak actin polymerisation in the cells. The optimal 
RANTES concentrations cause the same degree of induction of actin polymerisation 
induced by soluble mouse anti-human CD3 (UCHT1, 10 /xg/ml) (Fig. 3.12).
The effects of RANTES on actin polymerisation are also time dependent. Primary T 
lymphocytes were incubated with 1 ng/ml RANTES over a time course of 1 - 60 
minutes. RANTES induces optimal actin polymerisation within 10 minutes (Fig. 3.13).
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Fig. 3.1 Effect of RANTES on In Vitro Migration of Primary T Lymphocytes - dose response curve 
The effect of vehicle control ( □  ) and RANTES ( #  ) on in vitro migration of primary T lymphocytes. 
The cells were purified using plastic adherence then incubated with RANTES (0.1 - 100 ng/ml) in a 48- 
well microchemotaxis chamber for 4 hours, as described in Materials and Methods. Results are expressed 
as the mean number (±  SEM) of migrating cells in 5 high power magnification fields (400 x), from 
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Fig. 3.2 Effect of RANTES on In Vitro Migration of Primary T Lymphocytes - time course 
Primary T lymphocytes, purified by plastic adherence, were incubated with 1 ng/ml RANTES ( □  ) and 
10 ng/ml RANTES ( •  ) over a time course of 1 - 5 hours in a 48-well microchemotaxis chamber. 
Primary T lymphocytes were incubated with vehicle controls for 5 hours. Results are expressed as the 
mean number (±  SEM) of migrating cells in 5 high power magnification fields (400 x), from triplicate 
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Fig. 3.3 Effect of RANTES on In Vitro Migration of Jurkat T Cells
a) The effect of RANTES (0.1 - 100 ng/ml, •  ) and vehicle control ( □  ) on in vitro migration of Jurkat 
T cells. The cells were incubated for 4 hours in a 48-well microchemotaxis chamber and migration was 
assessed as described in Materials and Methods.
b) Jurkat T cells were incubated with 1 ng/ml RANTES ( □  ) and 10 ng/ml RANTES ( •  ) over a time 
course of 1 - 5 hours in a 48-well microchemotaxis chamber. Jurkat T cells were incubated with vehicle 
controls for 5 hours.
Results are expressed as the mean number (± SEM) of migrating cells in 5 high power magnification
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Fig. 3.4 Effect of RANTES on In Vitro Migration of Primary T Lymphocytes Purified From Whole 
Blood Packs
a) The effect of RANTES (0.1 - 100 ng/ml, •  ) and vehicle control ( □  ) on in vitro migration of 
primary T lymphocytes purified from whole blood packs. The cells were incubated for 4 hours in a 48- 
well microchemotaxis chamber and migration was assessed as described in Materials and Methods.
b) Primary T lymphocytes, purified from whole blood packs by plastic adherence, were incubated with 
1 ng/ml RANTES ( □  ) and 10 ng/ml RANTES ( •  ) over a time course of 1 - 5 hours in a 48-well 
microchemotaxis chamber. The cells were incubated with vehicle controls for 5 hours.
Results are expressed as the mean number (± SEM) of migrating cells in 5 high power magnification
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Fig. 3.5 Effect of RANTES on In Vitro Migration of Quiescent T Lymphoblasts
a) The effect of RANTES (0.1 - 100 ng/ml, •  ) and vehicle control ( □  ) on in vitro migration of 
quiescent T lymphoblasts. The cells were incubated for 4 hours in a 48-well microchemotaxis chamber 
and migration was assessed as described in Materials and Methods.
b) Quiescent T lymphoblasts were incubated with 1 ng/ml RANTES ( □  ) and 10 ng/ml RANTES ( •  
) over a time course of 1 - 5 hours in a 48-well microchemotaxis chamber. The cells were incubated with 
vehicle controls for 5 hours.
Results are expressed as the mean number (± SEM) of migrating cells in 5 high power magnification
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Fig. 3.6 Effect of RANTES on In Vitro Migration of PBMC Stimulated to Produce T Lymphoblasts 
The effect of RANTES (0.1 - 100 ng/ml, #  ) and vehicle control ( □  ) on in vitro migration of 
a)PBMC which had been stimulated for three days with PHA. b)PBMC which had been stimulated for 
72 hours with PHA, followed by incubation with IL-2 for 48 hours. c)PBMC which had been stimulated 
for three days with PHA, followed by incubation with IL-2 for four days. d)PBMC which had been 
stimulated for 72 hours with PHA, followed by incubation with IL-2 for 10 days.
The cells were washed then incubated for 4 hours in a 48-well microchemotaxis chamber and migration 
was assessed as described in Materials and Methods. Results are expressed as the mean number (±  SEM) 
of migrating cells in 5 high power magnification fields (400 x), from triplicate wells. Results are from 
a single representative experiment of at least three others performed.
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Fig. 3.7 Comparison of RANTES Induced Migration of Primary T Lymphocytes Purified bv Two 
Different Methods
The effect of vehicle control ( □  ) and RANTES ( •  ) on in vitro migration of primary T lymphocytes. 
The cells were purified by the two different methods, plastic adherence and using a R+D enrichment 
column. The cells were then incubated with RANTES (0.1 - 100 ng/ml) in a 48-well microchemotaxis 
chamber for 4 hours, as described in Materials and Methods. Results are expressed as the mean number 
(±  SEM) of migrating cells in 5 high power magnification fields (400 x), from triplicate wells. Results 




Fig 3.8 RANTES Induced Polarisation of Primary T Lymphocytes
Example of RANTES induced polarisation of primary T lymphocytes. RANTES induced T lymphocyte 
polarisation is indicated by 0
106
vehicle 0.1 10 100 1000
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Fig 3.9 RANTES Induced Polarisation of Primary T Lymphocytes - dose response curve 
Polarisation of T lymphocytes, purified by plastic adherence, treated with RANTES (0.1 - 1000 ng/ml, 
•  ) or vehicle control ( □  ). The cells were incubated with RANTES or vehicle control for 60 minutes. 
Results are expressed as the proportion of T lymphocytes that polarise after culture with RANTES. Each 
treatment was repeated in triplicate and each point is the mean ( ± SEM) of these triplicates. Results are 
from a single representative experiment of three others performed.
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Fig. 3.10 RANTES Induced Polarisation of Primary T Lymphocytes - time course 
Polarisation of T lymphocytes, purified by plastic adherence, treated with 1 ng/ml RANTES over a time 
course of 30 - 240 minutes ( ■  ). T lymphocytes were incubated with vehicle control for 240 minutes 
( □  ). Results are expressed as the proportion of T lymphocytes that polarise after culture with 
RANTES. Each treatment was repeated in triplicate and each point is the mean (±  SEM) of these 
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Fig 3.11 RANTES Induced Polarisation of Primary T Lymphocytes - comparison of purification methods 
Polarisation of T lymphocytes, purified by plastic adherence or purified using a R + D enrichment column, 
treated with RANTES (0.1 - 1000 ng/ml) or vehicle control. The cells were incubated with RANTES or 
vehicle control for 60 minutes. Results are expressed as the proportion of T lymphocytes that polarise 
after culture with RANTES. Each treatment was repeated in triplicate and each point is the mean (±  
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Fig. 3.12 RANTES Induced Actin Polymerisation of Primary T Lymphocytes - dose response curve 
T lymphocytes, purified by plastic adherence, were treated with RANTES (0.01 - 100 ng/ml, ■  ) or 
UCHT1 (10 /xg/ml, $$). The cells were incubated with RANTES or UCHT1 for 10 minutes, fixed, then 
the degree of actin polymerisation was assessed using FITC-phalloidin, which only binds to F-actin, not 
the unpolymerised form, see Materials and Methods. Results are from a single representative experiment 
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Fig. 3.13 RANTES Induced Actin Polymerisation of Primary T Lymphocytes - time course 
T lymphocytes, purified by plastic adherence, were treated with 1 ng/ml RANTES over a time course 
of 1 - 60 minutes ( ■  ). Cells were also treated with UCHTl (10 /xg/ml, 10 minutes, ) and vehicle 
control for 10 minutes ( □  ). The cells were fixed, then the degree of actin polymerisation was assessed 
using FITC-phalloidin, which only binds to F-actin, not the unpolymerised form, see Materials and 
Methods. Results are from a single representative experiment of three others performed.
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3.2 RANTES Activated Signalling Pathways
3.2.1 Effect of RANTES on T Lymphocyte Cytosolic Calcium Concentrations 
Addition of soluble mouse anti - human CD3 (UCHTl, 10 /xg/ml) to fiira-2 loaded 
Jurkat T cells significantly elevated ip <  0.01, two way analysis of variance) the basal 
[Ca2+], from a value of 38.5 ±  20.2 nM to 120 ±  18.5 nM (n = 4)(Fig. 3.14 a), b)). 
A signification elevation from a basal [Ca2+]j of 36.3 ±  14.1 nM to 370 ±  40.2 nM 
(n =  4) was also induced by in fura-2 loaded quiescent T lymphoblasts (Fig. 3.15 a), 
b)). Elevation of [Ca2+]i levels were detected 50 seconds after UCHTl treatment and 
the maximal increase was seen after 200 seconds. Addition of RANTES (10 ng/ml) did 
not significantly elevate basal [Ca2+]j in either Jurkat T cells (Fig. 3.14 c)) or quiescent 
T lymphoblasts (Fig. 3.15 c))(/i = 4).
UCHTl (10 /xg/ml) caused an increase in [Ca2+]i in primary T lymphocytes, purified 
by plastic adherence. Addition of UCHTl significantly elevated ip < 0.01, two way 
analysis of variance) the basal [Ca2+]j from a value of 32.5 ±3.23 nM to 112 ±  3.46 
nM (n — 4). with a maximal rise after 200 seconds (Fig. 3.16). In marked contrast, 
RANTES (0.1 - 100 ng/ml) during a 500 second observation period produced an 
elevation of 5.5 ±  1.66 nM {n = 4)(Fig. 3.17), which was not a significant difference 
from vehicle-treated cells. With the same preparations of lymphocytes, however, 
RANTES did induce migration (data not shown).
Thus we were unable to detect RANTES-induced changes in [Ca2+]i in any human T 
lymphocyte preparation.
3.2.2 Effect of RANTES on Phosphatidvlinositol Metabolism 
T lymphocytes were metabolically labelled with [32P]-orthophosphate and stimulated 
with UCHTl or RANTES. Phosphatidylinositol metabolism was assessed by examining 
[32P] - PtdOH production and PtdIns(4,5,)P2 breakdown, both indicators of PLC 
activation, as PtdOH acid is a breakdown product of diacylglycerol. The production 
of [32P] - labelled D-3 phosphoinositides was examined to investigate whether PI 3- 
kinase acitivty was induced. The results for p2P] - PtdOH production and PI(4,5)P2 
breakdown are expressed as a percentage of [32P] - Ptdlns to control for preparation 
variation as - Ptdlns levels should remain constant. The primary T lymphocyte 
[32P] - Ptdlns results were in the range of 0.8 - 1.7 * 10* cpm, much lower than the 
quiescent T lymphoblasts, which had levels of 8  - 20 * 104 cpm, suggesting that the 
primary T lymphocytes did not incorporate the [32P]-orthophosphate label adequately.
Addition of UCHTl (10 /xg/ml, 10 minute incubation) to a) quiescent T lymphoblasts 
and b) primary T lymphocytes, metabolically labelled with [32P]-orthophosphate, 
increased [32P] - phosphatidic acid (PtdOH) production in all preparations tested (Fig. 
3.18)(n = 3). The fold increase in [32P] - PtdOH production was 6.02 ±  2.3 for 
quiescent T lymphoblasts (n = 3) and 5.23 ±  3.6 for primary T lymphocytes in =  4). 
RANTES (1 ng/ml 30 - 600 second incubation) did not cause any detectable changes 
in [32P] - PtdOH production in quiescent T lymphoblasts or primary T lymphocytes (n 
= 3).
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P2P] - PtdIns(4,5)P2 levels were decreased following UCHTl stimulation (10 /xg/ml, 
10 minute incubation) in both a) quiescent T lymphoblasts and b) primary T 
lymphocytes, metabolically labelled with p2P]-orthophosphate (n =  3)(Fig. 3.19). P2P] 
- PtdIns(4,5)P2 breakdown was detected in all cells stimulated with UCHTl, inducing 
a fold decrease of [32P] - PtdIns(4,5)P2 levels by 2.3 ±  0.9 in quiescent T lymphoblasts 
(n = 3) and 3.2 ±  1.2 in primary T lymphocytes (n = 3). RANTES (1 ng/ml, 30 - 
600 second incubation) did not reduce the levels below vehicle controls.
D-3 phosphoinositides are minor fractions of the total phosphatidylinositol lipids so the 
D-3 phosphoinositide production results are not expressed as a fraction of the Ptdlns as 
the percentages would be small and changes difficult to detect, instead these results are 
expressed in cpm. UCHTl stimulation (10 /xg/ml, 10 minute incubation) did not affect 
the production of the D-3 phosphoinositide PtdIns(3)P consistently. [32P] - PtdIns(3)P 
levels were slightly raised above vehicle treated controls in quiescent T lymphoblasts 
(Tig. 3.20 a)), a fold increase of 3.2 ±  1.3 was detected, but not in primary T 
lymphocytes (n = 2)(Fig. 3.20 b)). RANTES (1 ng/ml, 30 - 600 second incubation) 
did not increase [32P] - PtdIns(3)P levels (n = 3).
P2P] - PtdIns(3,4)P2 levels were raised after stimulation with UCHTl (10 /xg/ml, 10 
minute incubation) of quiescent T lymphoblasts (Ilg. 3.21 a)) but not primary T 
lymphocytes (n = 3)(Fig. 3.21 b)). The increase in p2P] - PtdIns(3,4)P2 levels after 
UCHTl stimulation of quiescent T lymphoblasts was 2.2 ±  0.75 fold (n = 4). 
However, RANTES (1 ng/ml, 30 - 600 second incubation) did not produce any 
consistent effects on [32P] - PtdIns(3,4)P2 levels (n =  2).
UCHTl (10 ng/ml, 10 minute incubation) did cause an increase in [32P] - 
PtdIns(3,4,5)P3 levels in quiescent T lymphoblasts, with a 4.78 ± 1 . 9  fold increase 
above vehicle control levels (n = 2)(Fig. 3.22 a)), but no detectable effect on primary 
T lymphocyte [32P] - PtdIns(3,4,5)P3 levels (Fig. 3.22 b)). RANTES (1 ng/ml, 30 - 
600 second incubation) produced no increase above vehicle control levels in quiescent 
T lymphoblasts and primary T lymphocytes.
3.2.3 Effect of RANTES on In Vitro PI 3-Kinase Activity
D-3 phosphoinositide production was not detected after RANTES stimulation of primary 
T lymphocytes, so an alternative approach was used to determine whether RANTES, 
at concentrations found to be optimal for chemotaxis, could increase PI 3-kinase activity 
associated with PI 3-kinase immunoprecipitates. An analysis of the dose-response effect 
of RANTES (0.01 - 1000 ng/ml) revealed that low concentrations of RANTES (0.01 - 
1 ng/ml) produced a marked increase in PI 3-kinase activity in primary T lymphocytes, 
that was greater than that produced by the known PI 3-kinase activator, UCHTl (10 
/xg/ml)(Fig. 3.23). Greater increases in PI 3-kinase activity were produced by 10 to 
10000 ng/ml RANTES, with optimal responses following 10 to 100 ng/ml RANTES (n 
= 3).
In vitro kinase lipid activity of immunoprecipitates from RANTES (10 ng/ml) - 
stimulated primary T lymphocytes was increased in a time dependent manner (Fig. 
3.24). Elevation of PI 3-kinase activity above basal levels was evident 30 seconds post- 
RANTES and a peak increase in activity was observed 600 seconds post-RANTES. PI
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3-kinase activity had declined to 50% of peak value by 1800 seconds. This evidence 
implies that RANTES signalling is coupled to the PI 3-kinase signalling pathway.
3.2.4 Effects of Wortmannin on Primary T Lymphocyte Activation 
To determine whether RANTES coupling to PI 3-kinase is functionally relevant a 
specific PI 3-kinase inhibitor, such as wortmannin, was used in the RANTES functional 
assays.
Wortmannin (0.01 - 1000 nM) inhibits RANTES-induced migration of primary T 
lymphocytes. The T lymphocytes were pretreated with wortmannin for 10 minutes 
before being stimulated with RANTES (1 ng/ml) in the microchemotaxis assay. The 
inhibition of RANTES -induced migration by wortmannin was concentration dependent 
and also dependent upon the concentration of RANTES used (Fig. 3.25). Hence, 
wortmannin had an IC50 of 0.04 ±  0.01 nM (n = 3) and 0.11 ±  0.08 nM (n = 3), 
against 1 ng/ml and 10 ng/ml RANTES, respectively.
The inhibition of RANTES induced migration of primary T lymphocytes was not due 
to the ethyl acetate vehicle in which wortmannin was reconstituted. T lymphocytes 
were incubated with vehicle or ethyl acetate at concentrations corresponding to the ethyl 
acetate concentration present in the relative wortmannin solution, before stimulation 
with 1 ng/ml RANTES in a microchemotaxis assay (Fig. 3.26). The ethyl acetate 
vehicle controls did not inhibit the RANTES induced migration.
Wortmannin inhibited the polarising effects of RANTES on primary T lymphocytes,
m
purified by plastic adherence (Fig. 3.27). Primary T lymphocytes were pretreated with 
wortmannin (0.1 - 100 nM) for 10 minutes, and incubated with RANTES (10 ng/ml) 
for 1 hour. Wortmannin inhibited the polarising effect of RANTES over the 0.1 -100 
nM concentration range, with an IC50 of 0.5 ±  0.12 nM (n =  3). Total inhibition of 
RANTES-mediated increases in polarisation was seen, with concentrations of 
wortmannin between 1 and 10 nM.
RANTES -induced actin polymerisation was also inhibited by wortmannin pretreatment 
(Fig. 3.28). Primary T lymphocytes were pretreated with wortmannin (0.001 - 1000 
nM) for 10 minutes then incubated with 10 ng/ml RANTES for 10 minutes. The 
inhibitory effects of wortmannin on RANTES-induced actin polymerisation were dose 
dependent with an ICS0 of 0.1 nM. Maximal inhibition was detected over the 
wortmannin concentration range of 1- 100 nM (n = 3).
The effect of wortmannin on RANTES-induced PI 3-kinase activity in primary T 
lymphocytes was examined by pretreating the cells with wortmannin (0.01 - 1000 nM), 
followed by stimulation with 10 ng/ml RANTES for 10 minutes (Fig. 3.29). The 
induction of PI 3-kinase activity induced by RANTES was inhibited by wortmannin in 
a concentration dependent manner. Complete inhibition was achieved, with a 
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Fig. 3.14 Time Course of rCa++l: in Fura-2 Loaded Jurkat T Cells Stimulated with UCHTl and 
RANTES
Time course of [Ca2+]i in fura-2 loaded Jurkat T cells, as determined by the Photon Technology 
International software program, for formulae see. Section 2.9. The cells were activated with a) vehicle 
control, b) UCHTl (10 ftg/ml), c) 10 ng/ml RANTES. The traces were obtained from one experiment, 
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Fig. 3.15 Time Course of rCa++l; in fura-2 Loaded Quiescent T Lymphoblasts Stimulated with UCHTl 
and RANTES
Time course of [Ca2+]i in fura-2 loaded quiescent T lymphoblasts, as determined by the Photon 
Technology International software program. The cells were activated with a) vehicle control, b) UCHTl 
(10 /xg/ml), c) 10 ng/ml RANTES. The traces were obtained from one experiment, but are representative 























Fig. 3.16 Time Course of rCa++l: in fura-2 Loaded Primary T Lymphocytes Stimulated with UCHTl 
Time course of [Ca2+]; in fura-2 loaded primary T lymphocyte (purified by plastic adherence), as 
determined by the Photon Technology International software program. The cells were activated with a) 
vehicle control, and b) UCHTl (10 /xg/ml). The traces were obtained from one experiment, but are 













  *   .














































Fig. 3.17 Time Course of rCa++l  in fura-2 Loaded Primary T Lymphocytes Stimulated with RANTES 
Time course of [Ca2+]i in fura-2 loaded primary T lymphocytes (purified by plastic adherence) as 
determined by the Photon Technology International software program. The cells were activated with a) 
0.1 ng/ml RANTES, b) 1 ng/ml RANTES, c) 10 ng/ml RANTES, and d) 100 ng/ml RANTES. The 
control experimental results are shown in Fig. 3.15. The traces were obtained from one experiment, but 
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Fig. 3.18 Effect of UCHTl and RANTES on [” P1 - PtdOH Production in Quiescent T Lymphoblasts and 
Primary T Lymphocytes
Effect of vehicle control (30 - 600 second incubation, □  ), UCHTl (10 /xg/ml, 10 minute incubation, 
$$) and RANTES (1 ng/ml, 30 - 600 second incubation, ■  ) on P2?] - PtdOH production in a) quiescent 
T lymphoblasts and b) primary T lymphocytes, purified by plastic adherence. Phosphatidylinositol 
metabolism was analysed as described in Materials and Methods. All results are expressed as a percentage 
of [32P] - Ptdlns detected in the same sample. Results are from a single representative experiment of at 
least two others performed.
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Fig. 3.19 Effect of UCHTl and RANTES on P2P1 - PtdIns(4.5)P, Breakdown in Quiescent T 
Lymphoblasts and Primary T Lymphocytes
Effect of vehicle control (30 - 600 second incubation, □  ), UCHTl (10 /xg/ml, 10 minute incubation, 
$$ ) and RANTES (1 ng/ml, 30 - 600 second incubation, ■  ) on p2?] - PtdIns(4,5)P2 breakdown in a) 
quiescent T lymphoblasts and b) primary T lymphocytes, purified by plastic adherence. Phosphatidylino- 
sitol metabolism was analysed as described in Materials and Methods. All results are expressed as a 
percentage of [32P] - Ptdlns detected in the same sample. Results are from a single representative 



















Fig. 3.20 Effect of UCHT1 and RANTES on P2P1 - PtdlnsO^P Production in Quiescent T Lymphoblasts 
and Primary T Lymphocytes
Effect of vehicle control (30 - 600 second incubation, □  ), UCHT1 (10 /xg/ml, 10 minute incubation, 
) and RANTES (1 ng/ml, 30 - 600 second incubation, ■  ) on pT*] - PtdIns(3)P production in a) 
quiescent T lymphoblasts and b) primary T lymphocytes, purified by plastic adherence. 
Phosphatidylinositol metabolism was analysed as described in Materials and Methods. All results are 

























Fig. 3.21 Effect of UCHT1 and RANTES on P2P1 - PtdIns(3.4)P, Production in Quiescent T 
Lymphoblasts and Primary T Lymphocytes
Effect of vehicle control (30 - 600 second incubation, □  ), UCHT1 (10 /xg/ml, 10 minute incubation, 
) and RANTES (1 ng/ml, 30 - 600 second incubation, ■  ) on p2?] - PtdIns(3,4)P2 production in a) 
quiescent T lymphoblasts and b) primary T lymphocytes, purified by plastic adherence. Phosphatidylino- 
sitol metabolism was analysed as described in Materials and Methods. All results are expressed in cpm. 





















Fig. 3.22 Effect of UCHT1 and RANTES on f”P1 - PtdlnsO^.S^Pa Production in Quiescent T 
Lymphoblasts and Primary T Lymphocytes
Effect of vehicle control (30 - 600 second incubation, □  ), UCHT1 (10 /xg/ml, 10 minute incubation, 
) and RANTES (1 ng/ml, 30 - 600 second incubation, ■  ) on p2]?] - PtdIns(3,4,5)P3 production in 
a) quiescent T lymphoblasts and b) primary T lymphocytes, purified by plastic adherence. 
Phosphatidylinositol metabolism was analysed as described in Materials and Methods. All results are 
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Fig. 3.23 Effect of RANTES on PI 3-Kinase Activity - dose response curve
Effect of RANTES on PI 3-kinase activity in T lymphocytes, purified by plastic adherence. T 
lymphocytes were stimulated by RANTES (0.01 - 1000 ng/ml, ■  ), UCHT1 (10 /xg/ml, ^  ), or vehicle 
control ( □  ) for 10 minutes. The PI 3-kinase from cell lysates was immunoprecipitated, an in vitro lipid 
kinase assay was conducted and the labelled lipids were analysed, see Materials and Methods. The upper 
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Fig. 3.24 Effect of RANTES on PI 3-Kinase Activity - time course
Effect of RANTES over a time course of 10 to 1800 seconds on PI 3-kinase activity in T lymphocytes, 
purified by plastic adherence. T lymphocytes were stimulated by 10 ng/ml RANTES (■ ), or vehicle 
control ( □  ) for 10 minutes. The PI 3-kinase from cell lysates was immunoprecipitated, an in vitro lipid 
kinase assay was conducted and the labelled lipids were analysed, see Materials and Methods. The upper 
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Fig. 3.25 Effect of Wortmannin on RANTES-Induced Migration of T Lymphocytes 
Effect of wortmannin on RANTES-induced migration of T lymphocytes. T lymphocytes, purified by 
plastic adherence, were pretreated with wortmannin (0.01 - 1000 nM) for 10 minutes. The cells were then 
incubated with 1 ng/ml RANTES ( •  ) or vehicle control ( □  ) in a 48-well microchemotaxis chamber 
for 4 hours, as described in Materials and Methods. Results are expressed as the mean number ( ± SEM) 
of migrating cells in 5 high power magnification fields (400 x), from triplicate wells. Results are from 
a single representative experiment of at least three others performed.
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Fig. 3.26 Effect of Ethvl Acetate Vehicle on RANTES-induced Migration of T Lymphocytes 
Effect of ethyl acetate vehicle on RANTES-induced migration of T lymphocytes. T lymphocytes, purified 
by plastic adherence, were pretreated with % ethyl acetate at concentrations corresponding to the 
concentrations present in corresponding wortmannin solutions (0.01 - 1000 nM) for 10 minutes. The cells 
were then incubated with 1 ng/ml RANTES ( •  ) or vehicle control ( □  ) in a 48-well microchemotaxis 
chamber for 4 hours, as described in Materials and Methods. Results are expressed as the mean number 
(±  SEM) of migrating cells in 5 high power magnification fields (400 x), from triplicate wells. Results 
are from a single representative experiment of at least one other performed.
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Fig. 3.27 Effect of Wortmannin on RANTES-induced Polarisation of T Lymphocytes 
Effect of wortmannin on RANTES-induced polarisation of T lymphocytes. T lymphocytes, purified by 
plastic adherence, were pretreated with wortmannin (0.1 - 100 nM) for 10 minutes. The cells were then 
incubated with 10 ng/ml RANTES ( ■  ) or vehicle control ( □  ) for 60 minutes. Results are expressed 
as the proportion of T lymphocytes that polarise after culture with RANTES. Each treatment was repeated 
in triplicate and each point is the mean (±  SEM) of these triplicates. Results are from a single 
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Fig. 3.28 Effect of Wortmannin on RANTES-induced Actin Polymerisation of T Lymphocytes 
Effect of wortmannin on RANTES-induced actin polymerisation of T lymphocytes. T lymphocytes, 
purified by plastic adherence, were pretreated with wortmannin (0.001 - 1000 nM) for 10 minutes. The 
cells were then incubated with 10 ng/ml RANTES ( ■  ) or vehicle control ( □  ), fixed, and the degree 
of actin polymerisation was assessed using FITC-phalloidin, which only binds to F-actin, not the 
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Fig. 3.29 Effect of Wortmannin on RANTES-induced PI 3-Kinase Activity
Effect of wortmannin on RANTES-induced PI 3-kinase activity of T lymphocytes. T lymphocytes, 
purified by plastic adherence, were pretreated with wortmannin (0.01 - 1000 nM) for 10 minutes. The 
cells were then stimulated by 10 ng/ml RANTES ( ■  ), or vehicle control ( □  ) for 10 minutes. The 
PI 3-kinase from cell lysates was immunoprecipitated, an in vitro lipid kinase assay was conducted and 
the labelled lipids were analysed, see Materials and Methods. The upper panel is a TLC autoradiograph 
and the lower panel is a densitometric scan of the autoradiograph in arbitrary units (a.u.).
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3.3 Costimulation and RANTES
3.3.1 Modulation of T Lymphocyte Proliferation by RANTES 
Treatment of T lymphocytes, purified with a R+D column (which enables quicker 
preparation of the cells), a) with UCHT1 alone (0.01 -10  /xg/ml) or b) treatment with 
fixed CHO-B7+ cells alone (1 : 7 T cells -1  : 1 T cells) did not increase T lymphocyte 
proliferation consistently , although 1 - 1 0  /xg/ml UCHT1 did increase proliferation by 
a factor of 2 above vehicle control levels (Fig. 3.30).
Costimulation of the T lymphocytes with 0.01 /xg/ml UCHT1 and fixed CHO-B7+ cells 
(CHO-B7+ : T cell of 1:7, 1:5, 1:3, 1:1) did not induce proliferation but modulation 
of proliferation was observed with 0.1 /xg/ml UCHT1 plus CHO-B7+ . 1 /xg/ml
UCHT1 was more effective at inducing proliferation in combination with CHO-B7+ 
cells but the most effective stimulus was 10 /xg/ml UCHT1 plus CHO-B7+ cells. A 
ratio of 1 : 1 CHO-B7+ cells : T cells in combination with 10 /xg/ml UCHT1 caused 
the greatest increase in proliferation of T lymphocytes, but this ratio was difficult to use 
as large numbers of CHO-B7+cells were required (Fig. 3.31). Therefore a combination 
of 10 /xg/ml UCHT1 plus 1 CHO-B7+ : 3 T cells was used as the optimal costimulus.
Again, there were differences in the extent of proliferation seen with different donors, 
but the trends were always comparable between the different populations, e.g. 1 0  /xg/ml 
anti-CD3 and 1 CHO-B7+ : 3 T cells induced a 8.3 ± 1 . 7  fold increase in proliferation 
(n = 4).
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RANTES (0.01 - 100 ng/ml) did not increase proliferation of T lymphocytes above 
levels detected with vehicle treatment only (Pig. 3.32 a)). In combination with 10 
/xg/ml UCHT1, RANTES did not raise the level of proliferation seen with UCHT1 and 
vehicle only (Pig. 3.32 b)). Also, in combination with CHO-B7+ cells, RANTES did 
not increase proliferation above the level that was detected with CHO-B7+ cells alone 
(Pig. 3.32 c)). RANTES (0.01 - 100 ng/ml) did, however, potentiate T lymphocyte 
proliferation when purified T lymphocytes were costimulated with UCHT1 plus CHO- 
B7+ cells (Pig. 3.33). Peak potentiating effects were seen at 1 - 10 ng/ml RANTES. 
RANTES (1 ng/ml) produced a 55 ±  22.9 % (n = 4) potentiation of proliferation when 
added in combination with UCHT1 plus CHO-B7+ cells.
T lymphocytes were costimulated with UCHT1 (10 /xg/ml) plus CHO-B7+ in the 
presence of monoclonal anti-RANTES (5 - 0.005 /xg/ml) or a isotype matched control 
antibody (5 - 0.005 /xg/ml). Treatment of the primary T lymphocytes with anti- 
RANTES inhibits proliferation (Fig. 3.34). Anti-RANTES (5 /xg/ml) produced a 25 
± 5  % inhibition of proliferation (n =  4). The addition of an isotype matched control 
antibody was without effect. The inhibitory effects of anti-RANTES produced a curve 
that is the inverse of the characteristic "bell-shape-like" dose response curve which is 
normally seen with RANTES stimulation of T lymphocytes.
3.3.2 Costimulation of T Lymphocytes Modulates RANTES Peptide Production 
Primary T lymphocytes were stimulated with either vehicle, UCHT1 (10 /xg/ml), fixed 
CHO-B7+ cells, or a combined costimulation of UCHT1 plus CHO-B7+ cells for 0 - 
48 hours (Fig. 3.35). The concentration of RANTES peptide produced was low in
125
vehicle treated T lymphocytes and cells treated with UCHT1 or CHO-B7+ cells alone. 
The most effective stimulus for RANTES generation was a combination of UCHT1 plus 
CHO-B7+ cells. The increase in RANTES production was seen at 24 hours and 
continued to rise throughout the time course for these experiments. A set of RANTES 
generation experiments were performed over a longer time course. T lymphocytes were 
stimulated with either vehicle or costimulation of UCHT1 plus CHO-B7+ cells for 48 - 
96 hours (Fig. 3.36). Cells treated with costimulation produced high levels of 
RANTES which plateaued out at 48 hours of treatment. The actual increase in 
RANTES peptide production was largely dependent upon the cell preparations used, 
with T lymphocyte populations from different donors having different degrees of 
peptide production but costimulation consistently induced the highest release of peptide.
3.3.3 Modulation of IL-2 Receptor by RANTES
Purified T lymphocytes were stimulated with vehicle, UCHT1 (10 /xg/ml), CHO-B7+, 
or UCHT1 plus CHO-B7+ (Fig. 3.37). CD25 (IL-2 R) levels were increased after 
stimulation with UCHT1 plus CHO-B7+. UCHT1 or CHO-B7+ stimulation alone 
appeared to induce small increases in CD25 expression. RANTES (1 ng/ml) was then 
applied in addition to the previous treatments. RANTES in combination with the 
vehicle or UCHT1 did not potentiate CD25 expression. When T lymphocytes were 
stimulated with CHO-B7+ and RANTES, CD25 expression was increased above levels 
seen with CHO-B7+ alone. RANTES also potentiated the effect seen with UCHT1 plus 
CHO-B7+ on CD25 expression.
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RANTES, in combination with CHO-B7+ or UCHT1 plus CHO-B7+, switched on the 
expression of IL-2 R in cells that had been negative for this receptor, increasing the % 
total cells binding to FITC-labelled anti-CD25 (Pig. 3.38). RANTES potentiated the 
response seen to CH0-B7+ stimulation, with a 2.4 ±  0.8 fold increase in FITC-labelled 
anti-CD25 binding cells (n = 4), and the response seen to costimulation with UCHT1 
plus CHO-B7+, with a 1.8 i  0.6 fold increase (n = 4). In addition, RANTES, in 
combination with CHO-B7+ or UCHT1 plus CHO-B7+, upregulated the intensity of 
fluorescence of FITC-labelled anti-CD25 binding in cells constitutively expressing low 
levels of the marker, increasing the mean fluorescence per cell (Fig. 3.39).
3.3.4 Modulation of IL-2 Peptide Production bv RANTES
Primary T lymphocytes were stimulated with either vehicle, UCHT1 (10 /xg/ml), fixed 
CHO-B7+ cells, or a combined costimulation of UCHT1 plus CHO-B7+ cells for 48 
hours (Fig. 3.40). The concentration of IL-2 produced was calculated using a IL-2 
dependent cell line.
IL-2 production was low in vehicle treated T lymphocytes and cells treated with CHO- 
B7+ alone. UCHT1 stimulation of the T lymphocytes did increase IL-2 production but 
this increase was variable between different donors. The most effective stimulus for 
IL-2 generation was a combination of UCHT1 plus CHO-B7+ cells, with a 4.1 ±  1.9 
fold rise observed above vehicle control levels (n = 3).
RANTES (1 ng/ml) was then applied in addition to the previous treatments. RANTES 
in combination with the vehicle or UCHT1 or CHO-B7+ alone did not affect IL-2
production consistently, with small increases only observed in two out of four 
experiments and RANTES did not significantly potentiate the effect seen with UCHT1 
plus CHO-B7+ on IL-2 production. So RANTES had no effect on IL-2 production even 
in combination with CHO-B7+ plus UCHT1, although it does potentiate IL-2 R 
upregulation, in this situation.
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Fig, 3.30 Effect of UCHT1 and CHQ-B7* on Proliferation of Primary T Lymphocytes 
Effect of a) UCHT1 alone (0.01 - 10 /xg/ml, ) or b) treatment with CHO-B7+ as APC (CHO-B7+ 
: T cell of 1:7, 1:5, 1:3, 1:1, ■  ), or vehicle control ( □  ) on proliferation of purified T lymphocytes. 
T lymphocytes were purified using a R+D column then treated with UCHT1 or CHO-B7+ for 72 hours. 
Proliferation was measured by [3H] - thymidine incorporation (cpm x 1000), see Materials and Methods 
production. Each treatment was repeated in quadruplicate and the mean (± SEM) is shown.
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Fig. 3.31 Effect of UCHT1 Plus CHO-B7* on Proliferation of Primary T Lymphocytes
Effect of 0.01 - 10 /ig/ml UCHT1 with CH0-B7+ as APC (CHO-B7+ : T cell of 1:7, 1:5, 1:3, 1:1) on
proliferation of purified T lymphocytes.
T lymphocytes were purified using a R+D column then treated with UCHT1 and CHO-B7+ for 72 hours. 
Proliferation was measured by [3H] - thymidine incorporation (cpm x 1000), see Materials and Methods 
production. Each treatment was repeated in quadruplicate and the mean (± SEM) is shown.
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Fig. 3.32 Effect of RANTES on the Proliferation of Primary T Lymphocytes Induced bv UCHT1. or 
CHO-B7+
T lymphocytes were purified using a R+D column then stimulated with a) vehicle control ( □  ) or 
RANTES (0.01 - 100 ng/ml, ■  ), b) vehicle control ( □  ), or UCHT1 (10 /xg/ml) in the presence of 
RANTES (0.01 - 100 ng/ml, ■  ) or vehicle control ( ), c) vehicle control ( □  ), CHO-B7+ (1 : 3
T cells) in the presence of RANTES (0.01 - 100 ng/ml, ■  ) or vehicle control ( ), for 72 hours.
Proliferation was measured by [3H] - thymidine incorporation (cpm x 1000), see Materials and Methods 
production. Each treatment was repeated in quadruplicate and the mean (± SEM) is shown. Results are 
from a single representative experiment of three others performed.
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Fig. 3.33 Effect of RANTES on the Proliferation of Primary T Lymphocytes Induced by Costimulation 
Effect of RANTES in addition to costimulation of T lymphocytes. T lymphocytes were purified using a 
R+D column then stimulated with vehicle control, or costimulation with CHO-B7+ (1 CHO-B7+ : 3 T 
cells) and UCHT1 (10 /xg/ml) in the presence of RANTES (0.01 - 100 ng/ml, ■  ) or vehicle control ( 
) for 72 hours. Proliferation was measured by [3H] - thymidine incorporation (cpm x 1000), see 
Materials and Methods production. Each treatment was repeated in quadruplicate and the mean (± SEM) 
is shown. Results are from a single representative experiment of three others performed.
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Fig. 3.34 Effect of Anti-RANTES on the Proliferation of Primary T Lymphocytes Induced bv 
Costimulation
Effect of anti-RANTES to costimulation of T lymphocytes. T lymphocytes were purified using a R+D 
column then stimulated with vehicle control, or costimulation with CHO-B7+ (1 CHO-B7+ : 3 T cells) 
and UCHT1 (10 /xg/ml) in the presence of anti-RANTES (5 - 0.005 /xg/ml, ■  ) or IgG control antibody 
(5 - 0.005 /xg/ml, ) for 72 hours. Proliferation was measured by pH] - thymidine incorporation (cpm 
x 1000), see Materials and Methods production. Each treatment was repeated in quadruplicate and the 
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Fig. 3.35 Costimulation of Primary T Lymphocytes Induces RANTES Peptide Production 
Costimulation of T lymphocytes with CHO-B7+ and UCHT1 induces RANTES peptide production. T 
lymphocytes were purified using a R+D column then stimulated with either vehicle ( □  ), UCHT1 (10 
/xg/ml, ▲ ), CHO-B7+ (1:3 T cells, •  ), or a combination of UCHT1 and CHO-B7+ ( ▼ ) for 0 - 48 
hours. The RANTES peptide levels were assessed by ELISA, see Material and Methods. Results are from 
a single representative experiment of three others performed.
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Fig. 3.36 Costimulation of Primary T Lymphocytes Induces RANTES Peptide Production which Plateaus 
After 96 Hours
T lymphocytes purified using a R + D column were stimulated with either vehicle ( □  ), or UCHT1 (10 
/xg/ml) and CHO-B7+ (1 : 3 T cells, ■ ) for 48 - 96 hours. The RANTES peptide levels were assessed 
by ELISA, see Material and Methods. Each treatment was repeated in triplicate and the means (±SEM) 
are shown. Results are from a single representative experiment of three others performed.
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Fig, 3.37 RANTES Modulates the IL-2 Receptor in Primary T Lymphocytes After Costimulation - FACS Traces
T lymphocytes purified using a R+D column were stimulated with either a) vehicle, or b) UCHT1 (10 /ig/ml), or c) CHO-B7+, or d) costimulation with UCHT1 
(10 /xg/ml) and CHO-B7+ (1 : 3 T cells). These treatments were repeated in the presence of 1 ng/ml RANTES for 48 hours e) 0  g) h), respectively. The cells were 
then stained with FITC-labelled anti-CD25 (anti-IL-2 R), see Material and Methods. Fluorescence intensity was calculated using a FACS vantage, 10 000 viable cells 
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Fig. 3.38 RANTES Modulates the IL-2 Receptor in Primary T Lymphocytes After Costimulation - 
assessed bv FITC-stained cells as a proportion of total cells
T lymphocytes purified using a R + D column were stimulated with either vehicle, or UCHT1 (10 /xg/ml), 
or CHO-B7+, or costimulation with UCHT1 (10 /tg/ml) and CHO-B7+ (1 : 3 T cells) in the presence of 
vehicle ( □  ) or 1 ng/ml RANTES ( ■  ) for 48 hours. The cells were then stained with FITC-labelled 
anti-CD25 (anti-IL-2 R), see Material and Methods. Results are expressed as FITC stained T cells as a 
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Fig. 3.39 RANTES Modulates the IL-2 Receptor in Primary T Lymphocytes After Costimulation - 
assessed by mean FITC-fluorescence
T lymphocytes purified using aR+D column were stimulated with either vehicle, or UCHT1 (10 /tg/ml), 
or CHO-B7+, or costimulation with UCHT1 (10 /ig/ml) and CHO-B7+ (1 : 3 T cells) in the presence of 
vehicle ( □  ) or 1 ng/ml RANTES ( ■  ) for 48 hours. The cells were then stained with FITC-labelled 
anti-CD25 (anti-IL-2 R), see Material and Methods. Results are expressed as mean FITC fluorescence 
and data is from the same samples analysed in Fig. 3.38. Results are from a single representative 
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Fig. 3.40 Modulation of IL-2 Peptide Production bv RANTES
T lymphocytes purified using a R + D column were stimulated with either vehicle, or UCHT1 (10 /rg/ml), 
or CHO-B7+, or costimulation with UCHT1 (10 /xg/ml) and CHO-B7+ (1 : 3 T cells) in the presence of 
vehicle ( □  ) or 1 ng/ml RANTES ( ■  ) for 48 hours. The supernatants were then removes and IL-2 
production was assayed using an IL-2 dependent cell line. Results are from a single representative 
experiment of two others performed.
SECTION FOUR
DISCUSSION
4.1 Migration of T Lymphocytes
4.1.1 Induction of Migration of Primary T Lymphocytes bv RANTES
RANTES induces the migration of CD4+/CD45RO+ cells, memory T lymphocytes in 
vitro (Schall et al. 1990). To determine the effects of RANTES on the migration of 
human T lymphocytes, we performed a series of microchemotaxis chamber assays on 
primary T lymphocytes, T lymphoblasts and the Jurkat leukaemic T cell line.
RANTES induced migration of primary T lymphocytes that had been purified by either 
plastic adherence or by using a R+D enrichment column. Either method produced a 
very high yield of CD3+ cells with few contaminating monocytes, NK cells, or B 
lymphocytes. The yield, purity, and the extent of migration was not affected by the 
purification method. The chemotactic effect of RANTES was concentration dependent, 
with 1 - 1 0  ng/ml being the optimal concentration, and time dependent. The actual 
number of cells migrating was largely dependent upon the cell preparation used, with 
different T lymphocyte populations from different donors having a marked difference 
in response to the agonists.
It is important to note that leukocyte migration induced by chemicals can be classed as 
either chemokinesis or chemotaxis (see 3.1.2). Chemokinesis is the change in speed 
or rate of random turning of cells induced by chemicals in the environment. In 
comparison, chemotaxis is the directed migration of cells in response to a chemical
stimulus. Most chemotactic agents will also stimulate chemokinesis but it is important 
to differentiate between the two. This can be done in the 48-well microchemotaxis 
assay by performing a checkerboard analysis. Chemotaxis involves vectorial migration 
along a chemoattractant gradient so abolition of this gradient by placing equal 
concentrations of the chemoattractant in the upper and lower wells of the chamber, will 
result in decreased migration of the response is chemotactic (Farrar et al. 1985). This 
was the case for the RANTES induced migration, thus RANTES is chemotactic for T 
lymphocytes, inducing their vectorial migration.
The RANTES induced migration results confirmed what had been shown by previous 
studies, the optimal RANTES concentration range of 1 - 10 ng/ml and the "bell-shape- 
like" concentration dependent response curve is consistent throughout the different 
studies (Schall et al. 1990; Murphy et al. 1994; Taub et al. 1993; Bacon et al. 1995). 
Incubation times are also consistent with 3 - 4  hours causing optimal RANTES induced 
migration studies. One exception is work by Schall et al (Schall et al. 1990), where 
cells were only incubated with RANTES for one hour but an incubation time response 
curve is not included in this work so it is difficult to ascertain whether they are 
detecting optimal migration at this incubation time point of one hour.
4.1.2 Induction of Migration of Alternative Sources of T Lymphocytes by RANTES 
The same assays were also used on purified T lymphocytes from whole blood packs. 
RANTES did not induce any migration above vehicle control levels in these T 
lymphocyte populations. The Blood Transfusion Service will not release whole blood 
packs until biohazard screening results have been obtained. Therefore, the blood packs
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were four days old by the time of purification so the lack of response to RANTES could 
be explained by the T lymphocytes losing their responsiveness to RANTES after four 
days in storage. The storage time might have led to downregulation of RANTES 
receptors, or problems with RANTES binding, or disruption of the normal intracellular 
signalling pathways. This was unfortunate as the whole blood packs were potentially 
a good source of large numbers of lymphocytes.
There are two other good sources of large numbers of T lymphocytes : T cell lines, 
such as the Jurkat cell line and T lymphoblasts, which can be cultured in relatively 
large amounts. Jurkat T cells did not respond to RANTES in the microchemotaxis 
assay and no other groups have shown these cells migrating in response to RANTES. 
The quiescent T lymphoblasts did not respond either to RANTES in this assay. Even 
at very early stages of T lymphoblast preparation no chemotaxis was observed in 
response to RANTES, so the response that is seen in primary T lymphocytes is lost at 
a very early stage even after 3 days PHA stimulation.
The transformation processes that have been performed to produce the Jurkat T cells 
and T lymphoblasts may be the reason as to why there is no migratory response to 
RANTES by these cells. The transformation processes may have led to i) the 
downregulation of the RANTES receptor, ii) disruption or modification of the receptor 
signalling coupling processes, or iii) disintegration of the full intracellular signalling 
pathways needed for migration, but as no RANTES receptor has been cloned that is 
found in T lymphocytes, and the signalling pathways involved in RANTES activation 
are still not fully identified, this is difficult to investigate (Gao et al. 1993; Neote et al. 
1993).
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One of the problems with the work that has been carried out into identifying the 
RANTES receptor on T lymphocytes is that it has been assumed that this receptor will 
be G protein linked. The oligonucleotides that have been produced to screen different 
cDNA libraries and used in Polymerase chain reactions have been based on that 
assumption (Neote et al. 1993). Therefore other oligonucleotides should be made based 
on amino acid sequences from cytokine receptors that are not G protein linked, but say 
tyrosine kinase linked such as IL-2 or IFN-a receptor (DeFranco, 1993). These 
oligonucleotides could then be used as primers in reverse transcription polymerase chain 
reaction (PCR) using a primary T lymphocyte cDNA library. After molecular cloning 
and sequencing of the PCR products, new novel clones may be identified. These then 
could be expressed in cell lines such as human embryonic kidney 293 cells to be able 
to characterise these receptors fully. In addition, soluble constructs of the C-C CKR1 
could be tagged either radioactively or with a fluorescent tag and binding studies could 
be performed to establish whether this receptor is present on primary T lymphocytes.
The inability of RANTES to induce migration of T lymphoblasts or Jurkat T cells and 
the lack of chemokine studies performed on T cell lines, that were readily available, 
indicated that primary T lymphocytes purified from venous blood donations should be 
used in all the later work.
4.1.3 Other Models of Lymphocyte Migration
The 48-well microchemotaxis assay has several limitations. The membrane is a non- 
physiological surface for lymphocyte adhesion or migration and all the normal 
endothelial and extracellular matrix adhesion molecules are absent. More physiological
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studies have utilised a transendothelial chemotaxis assay with human umbilical vein 
endothelial cell monolayers (HUVEC) grown on the membranes (Roth et al. 1995). 
RANTES induced chemotaxis of primary T lymphocytes in this HUVEC migration 
assay system similarly to the 48-well microchemotaxis assay with preferential migration 
of CD45RO+ cells. The optimal concentrations for RANTES in these assays were 
again in the 1 - 10 ng/ml range. Another group has used a human/severe combined 
immune deficient (SCID) mouse model where SCID mice received human primary T 
lymphocytes followed by subcutaneous injections of RANTES. RANTES induced 
migration of lymphocytes, so that lymphocyte accumulation was detected in the skin and 
tissue from the injection sites (Murphy et al. 1994).
4.2 Other Chemotactic Effects of RANTES on T Lymphocytes 
Non-motile cells are spherical and the actin filaments present in the cytoskeleton are 
uniformly distributed. After stimulation of T lymphocytes via TCR coupled 
mechanisms, there is a large increase in actin polymerisation causing the formation of 
a dense F-actin collar around the outside of T lymphocytes. This collar is then replaced 
by the production of enlarged uropods, cytoplasmic projections rich in F-actin, 
increasing the length of the cell edge, and so polarising the cell shape into that seen in 
motile cells (Parsey & Lewis, 1993). These uropods are then thought to attach to the 
substrate, before the cell body moves up over the attachment during migration 
(Wymann et al. 1990).
This is supported by studies using time lapse photography and lymphocyte migration 
through collagen gels which show that the cells observed to move, were also the ones
that were polarised, and the proportion of cells changing shape was similar to the 
proportion of cells translocating through the collagen gels (Wilkinson, 1986).
Thus, two other assays were performed to study the chemotactic effects of RANTES 
in more detail. The effects of RANTES on polarisation, indicating shape change, and 
the effects of RANTES on actin polymerisation.
4.2.1 Induction of Polarisation of T Lymphocytes by RANTES 
RANTES induced a concentration dependent polarisation response in primary T 
lymphocytes which was also time dependent. Optimal polarisation was seen at 1 - 10 
ng/ml RANTES, the same concentrations of peptide that are necessary for maximum 
migration. This response was seen at 1 hour which is prior to the optimal time for 
chemotaxis of four hours suggesting that RANTES induces shape change in the T 
lymphocytes before they migrate. Our results are supported by a study by del Pozo et 
al (del Pozo et al. 1995), who not only showed that RANTES can induce polarisation 
of T lymphocytes, but also caused the redistribution of adhesion molecules such as 
ICAM-1 and ICAM-3 to the uropod suggesting that RANTES could have an additional 
role in cell adhesion.
Interestingly it was T lymphoblasts that were used by del Pozo et al, illustrating that 
T lymphoblasts can be responsive to RANTES in polarisation studies but their work did 
not include migration assays (del Pozo et al. 1995). These findings and the inability 
of RANTES to induce migration of T lymphoblasts would suggest that T lymphoblasts 
have functioning RANTES receptors and the signalling pathways involved in
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polarisation are intact, but migration cannot be induced by RANTES. Thus, a factor 
that is downstream of T lymphocyte polarisation, but upstream of migration is missing 
in T lymphoblasts, perhaps the lack of integrins. Integrins, such as a ^ ,  undergo 
transient interactions with immunoglobulins, such as MAdCAM-1, on the blood vessel 
walls, which allows for "rolling" of the lymphocytes along the endothelium, which is 
then followed by an activation signal from chemoattractants causing the firm adhesion 
between integrin molecules on the lymphocytes and immunoglobulin superfamily ligands 
on the endothelium, such as LFA-l/ICAM-1 or ICAM-2 or ICAM-3, a 4i y  MAdCAM- 
1, and a4i y  VC AM interactions, leading to lymphocyte transmigration into the tissues 
(Ager, 1994).
Polarisation studies were carried out on T lymphocytes purified by the plastic adherence 
method and using a R+D enrichment column from the same whole blood donation. The 
method of purification did not affect the extent of polarisation induced by RANTES. 
Cells that had been purified by plastic adherence compared to those that had been 
prepared using a R+D enrichment column, did not respond differently in the 
polarisation assays. This data and the data from the migration assays assured us that 
when the enrichment column was used for quicker preparation of the cells, the method 
of preparation was not going to be a factor in the T lymphocyte responses to RANTES.
RANTES specifically induces the migration of CD45RO+ cells, memory T lymphocytes 
(Schall et al. 1990) so the differences in the amplitude of RANTES induced migration 
and polarisation of different T lymphocyte populations may have been due to the T 
lymphocyte subsets present in the populations studied. This would be especially valid 
if there was major variation in the number of CD45RO+ T lymphocytes present.
156
However, there was no obvious difference in the number of CD45RO+ cells in the 
populations from five different donors, that could explain the varying responses to 
RANTES in the polarisation assays. Thus, the CD45RO+ /CD45RA+ ratio variation 
in the different populations is not likely to be responsible for the different extents of 
effects induced by RANTES. However, the relatively small proportion of T 
lymphocytes responding to RANTES would still suggest that it is a subset of T 
lymphocytes which are RANTES responsive, and the inability to detect significant 
variation in the number of CD45RO+ T lymphocytes present, may have just been a 
feature of the lymphocyte populations we examined, or the assay was not sufficiently 
sensitive to be able to pick up minor variations.
4.2.2 Induction of Actin Polymerisation in T Lymphocytes by RANTES 
Actin polymerisation was induced by RANTES in the primary T lymphocytes in a 
concentration and time dependent manner. Optimal actin polymerisation was detected 
at 1 0  minutes, a far earlier optimal time point than that seen for polarisation and 
chemotaxis induced by RANTES. Thus, actin polymerisation seems to be a much 
earlier event than either polarisation or migration induced by RANTES. This observed 
actin polymerisation and resulting shape change may allow the T lymphocytes to more 
effectively probe the adjacent contact surface for other activating ligands.
Characteristic "bell-shape-like" concentration dependent response curves were observed 
in all three of the assays. An explanation for this observation, when it was noted by 
other groups in chemotaxis assays, was that high concentrations of RANTES promoted 
adherence of the T lymphocytes and hence less locomotion (Bacon et al. 1990).
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Another possibility is that high concentrations of the chemokine downregulate the 
RANTES receptor and so reduce the chemotactic effects.
The optimal concentration of RANTES which induced peak responses in the chemotaxis 
assays, polarisation assays and actin polymerisation assays was constant at 1 - 1 0  ng/ml. 
This suggests that these responses are all downstream events of RANTES binding to a 
similar receptor or receptors that have a similar efficacy. The ability of RANTES to 
act on resting primary T lymphocytes implies that sufficient high affinity receptor is 
expressed by these T lymphocytes to enable them to respond to RANTES prior to 
exposure to antigens.
It had been hoped by Schall et al, when they isolated the gene for RANTES, that 
RANTES would be a specific chemoattractant for T lymphocytes but RANTES is also 
a chemoattractant for eosinophils, monocytes, basophils and the three receptors that 
have been identified that bind RANTES, C-C CKR1, C-C CKR2 and C-C CKR4, bind 
M IP-la and MCP-1 in addition (Wang et al. 1993; Van Riper et al. 1994; Combadiere 
et al. 1995a; Power et al. 1995). This is analagous to the IL-2R 7 -chain which is an 
indispensable component of the IL-2R, as well as of the IL-4, IL-7 and IL-15 receptors 
(Taga & Kishimoto, 1995). More recently, a chemokine called lymphotactin has been 
isolated that specifically regulates both T lymphocyte and B lymphocyte migration. 
Clearly, lymphotactin has the potential of being an important molecule in the regulation 
of lymphocyte trafficking. However, the possibility that RANTES causes the selective 
attraction of T lymphocytes of the memory phenotype, could explain how specific 
subsets of T lymphocytes are targeted, and may give an indication as to the workings 
of T cell memory (Schall et al. 1990).
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4.3 Signalling Pathways and RANTES
The chemoattractant effect of RANTES is well established but the signalling pathways 
resulting in this effect are not defined. Two pathways were studied in detail: the 
classical phosphoinositide signalling pathway which involves PLC activation, resulting 
in PtdIns(4,5)P2 breakdown and calcium mobilisation and the PI 3-kinase signalling 
pathway, which causes D-3 phosphoinositide production.
4.3.1 Classical Phosphoinositide Signalling Pathway and RANTES 
Evidence has suggested that PLC signalling pathway and the corresponding calcium 
fluxes are activated by the majority of chemotactic ligands in several systems (Berridge, 
1993; Bacon et al. 1993). For instance, several groups have shown that C-C 
chemokines induce calcium fluxes in monocytes (Wang et al. 1993), eosinophils (Rot 
et al. 1992; Bourne et al. 1995; Kapp et al. 1994), and basophils (Bischoff et al. 1993). 
In this study we examined the effcet of RANTES on calcium mobilisation in primary 
human T lymphocytes. Anti-CD3 (UCHT1) induced a rise in [Ca2+]i in Jurkat T cells, 
quiescent T lymphoblast and primary T lymphocytes. This rise has also been shown 
to correspond with Ins(l,4,5)P3 formation in Jurkat cells, and indicates the involvement 
of an intact phospholipase C signalling pathway (Ward & Cantrell, 1988; Imboden & 
Stobo, 1985). Quiescent T lymphoblasts are readily loaded with fura-2, unlike the 
primary T lymphocytes. This is seen clearly in the response to UCHT1 which causes 
a ten fold increase in [Ca2+]i as compared to the response of primary T lymphocytes to 
UCHT1 which only induces a three fold increase. There is also a fluctuation in the 
basal [Ca2+]i levels in the fura-2 loaded primary T lymphocytes which would indicate 
that the cells have not loaded properly and that fura- 2  is leaking out of the cells and
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binding to the extracellular calcium added to the cell suspension. This poor loading 
may be a reason why nearly all the studies performed on [Ca2+]i fluxes in T 
lymphocytes have been performed on T cell lines or T lymphoblasts, not freshly 
isolated cells (Ward & Cantrell, 1989; Bacon et al, 1995).
RANTES (0.1 - 100 ng/ml) did not induce a detectable elevation of basal levels of 
[Ca2+]i in primary T lymphocytes, or Jurkat T cells or quiescent T lymphoblasts. The 
data from the experiments performed on Jurkat T cells and quiescent T lymphoblasts 
could be explained due to a lack of functioning RANTES receptors, as we could not 
detect RANTES induced migration in these types of T cell populations either. 
Chemotaxis control experiments were performed on the same populations of primary 
T lymphocytes used in these calcium experiments, and RANTES always induced 
migration of the T lymphocytes, so the lack of calcium mobilisation in response to 
RANTES is not due to a complete lack of response to RANTES, by the primary T 
lymphocytes.
Reasons for the lack of a calcium mobilisation response induced by RANTES are 
unclear. However, it may be that calcium fluxes in specific subsets of the T 
lymphocyte population cannot be detected using the fluorometric method, especially if 
the poor loading of fura-2 in the primary T lymphocytes is considered. This possibility 
is highlighted by the small proportion of T lymphocytes that respond to RANTES in the 
polarisation assay and the previous studies indicating that only specific subsets of T 
lymphocytes migrate in response to RANTES. These problems could be overcome by 
using a more sensitive assay to look at calcium mobilisation in individual cells, not just 
a cell suspension, such as a FACS (fluorescence activated cell sorter) assay to study
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each individual cell, loaded with calcium sensitive dye (Brooks et al, 1995). This 
method would allow cells that exhibit calcium fluxes in response to RANTES, to be 
selectively sorted and then their phenotype could be assessed. Thus, the RANTES 
responsive T lymphocyte subsets could be identified.
A recent report by Bacon et al, showed RANTES inducing biphasic mobilisation of 
[Ca2+]j in T helper cell clones (Bacon et al. 1995), which contradicts the findings in this 
study. Possible reasons for this discrepancy are : i) a different fluorescent [Ca2+]£ 
indicator was used, indo- 1  acetoxymethyl ester, instead of fura - 2  which was used in 
this study, ii) the concentration of RANTES used to stimulate the T cells were 10 -100 
fold higher concentrations than that produce optimal migration, although there is no 
indication of what concentration of RANTES is seen at the receptor, especially as 
RANTES may exist as a dimer in solution (see 1.2.1), and iii) the responses were only 
seen in a T helper cell line not in Jurkat T cells. Loetscher et al, also, have reported 
calcium fluxes after RANTES stimulation of CD4+ and CD8 + T cell clones. However 
the responses observed were only two fold increases above basal [Ca2+]i and the work 
was not repeated in primary T lymphocytes (Loetscher et al. 1994). The data presented 
in this study, however, indicates that chemotaxis of T lymphocytes, as determined 
under the in vitro conditions described, is not mediated by significant changes in 
intracellular calcium levels and assocaited downstream effector events.
Activation of quiescent T lymphoblasts and primary T lymphocytes by UCHT1 
increased the levels of phosphatidic acid (PtdOH), a product of diacylglycerol 
metabolism and therefore an alternative indicator of PLC activation. However, PtdOH 
can also be a product of PLD activation, so PtdIns(4,5)P2 levels were examined, in
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addition, to indicate PLC activation. PtdIns(4,5)P2 levels in the quiescent T 
lymphoblasts and primary T lymphocytes did appear to be reduced after UCHT1 
stimulation. This supports the PtdOH findings and demonstrates that anti-CD3 
stimulation results in activation of the phospholipase C signalling pathway. However, 
RANTES stimulation, did not alter the levels of either PtdOH or PtdIns(4,5,)P2 in either 
of the cell populations. This evidence confirms the results from the calcium 
determination experiments which indicated that the phospholipase C signalling pathway 
is not involved in RANTES stimulation of T lymphocytes.
4.3.2 PI 3-Kinase Signalling Pathway and RANTES
In mammalian cells, PI 3-kinase has been shown to associate, after receptor activation, 
directly or indirectly with numerous growth factors, including the IL-4 receptor and IL- 
2 receptor (Izuhara & Harada, 1993) and is coupled to CD28 (Ward et al. 1993; Pages 
et al. 1994; Truitt et al. 1994, Prasad et al. 1994), CD3 (Exley et al. 1994), CD4 
(Thompson et al. 1992) T cell antigens. The D-3 phosphoinositide lipids, particularly 
PtdIns(3,4,5)P3 generated by PI 3-kinase activity, have been postulated to act as second 
messenger molecules and implicated in the regulation of cell growth and proliferation.
The activation of PI 3-kinase by a specific receptor should lead to the accumulation of 
D-3 phosphoinositides such as PtdIns(3,4,5)P3. These lipids are generally measured 
after metabolic labelling of cells with [32P]-orthophosphate, as described in Materials 
and Methods. However, D-3 phosphoinositides form only a minor fraction of the total 
lipid content, and detection of D-3 phosphoinositide accumulation following receptor 
ligation, in vivo, requires substantial cell numbers and adequate radiolabelling of the
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phospholipids with f 2P]-orthophosphate.
We were unable to generate sufficient primary T lymphocyte numbers from freshly 
purified blood to enable the detection of D-3 phosphoinositides at a satisfactory level, 
as the radiolabelling of the resting primary cells was poor. For instance, the efficiency 
of radiolabelling was assessed by examining the number of cpm in the Ptdlns pool. 
Thus, the radioactivity in the Ptdlns pool of primary T lymphocytes was in the range 
of 0.8 - 1.7 x 104 cpm, compared to the radioactivity in quiescent T lymphoblasts, 
which was in the range of 8  - 20 x 10* cpm . Thus, radiolabelling of quiescent T 
lymphoblasts was not a problem, but RANTES did not increase D-3 phosphoinositide 
accumulation. Again, this lack of response to RANTES could be due to the inability 
of T lymphoblasts to bind RANTES, not necessarily because RANTES does not activate 
PI 3-kinase, although the work by del Pozo et al, indicates that T lymphoblasts may 
have RANTES receptors (del Pozo et al. 1995). However, this group did not examine 
the PI 3-kinase signalling pathways.
RANTES did induce PI 3-kinase activity in primary T lymphocytes in vitro as assessed 
by : i) the increase in lipid kinase activity in anti-p85 subunit immunoprecipitates,
ii) the inhibition by wortmannin, a specific PI 3-kinase inhibitor, of the RANTES 
induced chemotaxis, polarisation and actin polymerisation, and iii) the inhibition by 
wortmannin of the RANTES induced lipid kinase activity seen in anti-p85 subunit 
immunoprecipitates.
Howver, some important control experiments should be performed to clarify these 
results. Firstly, the lipid product of the anti-p85 subunit immunoprecipitates should be
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analysed by quantitative HPLC to check that it is 3-phosphorylated lipids that have been 
produced not 4-phosphorylated lipids, confirming that the anti-p85 immunoprecipitated 
PI 3-kinase activity. This however may not be possible as only low levels of 
radiolabelled product were obtained. Alternatively, the immunoprecipitates could be 
examined for their sensitivity to adenosine (300 *xM) and detergents such as NP40 (0.5 
%). PI 3-kinase is inhibited in the presence of detergent but not affected by adenosine, 
whereas PI 4-kinase is inhibited by adenosine but not affected in the presence of 
detergents (Cochet et al. 1991, Ward et al. 1992b). Western blot analysis could also 
be used to analyse the quantity of protein being immunoprecipitated, to ensure that the 
observed changes in PI 3-kinase activity are not just a result of differences in quantities 
of protein.
As the peak induction of PI 3-kinase activity occurs at 10 minutes post-RANTES and 
the maximum actin polymerisation occurs at a similar time point, this implies a 
significant role for a PI 3-kinase in actin polymerisation of primary T lymphocytes. In 
comparison, chemotaxis and polarisation occur at much later time points, suggesting the 
involvement of other signalling mechanisms distal to PI 3-kinase. However, the marked 
inhibitory effect of wortmannin on polarisation and chemotaxis indicates a key role for 
PI 3-kinase.
Our studies also support the existence of several PI 3-kinase isoforms with different 
sensitivities to wortmannin which are activated in vivo by RANTES, as the functional 
effects of chemotaxis including migration, polarisation and actin polymerisation are 
more sensitive to wortmannin inhibition, with an IC50 of between 0.04 - 0.5 nM, than 
the in vitro kinase activity upregulated by RANTES, which wortmannin inhibits with
an IC5 0  in the range of 10 - 100 nM.
PI 3-kinase activation has been implicated in cell growth and proliferation, sorting and 
trafficking of proteins in eukaryotic cells (Volinia et al. 1995), and actin 
polymerisation. The role of PI 3-kinase activation in protein trafficking may be 
particularly relevant to migration, as these responses require substantial cytoskeletal 
reorganisation. In addition, D-3 phosphoinositides can activate PKC isoenzymes such 
as PKC5, £, f  and 17. Phatak et al have shown that PKC activation is important in actin 
polymerisation. Engagement of the TCR by anti-CD3 causes a rapid increase in actin 
polymerisation in T lymphocytes but the concomitant rise in [Ca2+]i was not necessary 
nor sufficient for the F-actin increase, as calcium ionophores caused a similar rise in 
[Ca2+]i but had no effect on F-actin (Phatak & Packman, 1994). However, inhibitors 
of PKC lowered the resting cellular F-actin and partially blocked the increase in F-actin 
caused by anti-CD3 but had no effect on [Ca2+]i, indicating a role for PKC in actin 
polymerisation, independent of calcium mobilisation. One of the major intracellular 
PKC substrates, PKC substrate protein, cross links F-actin when dephosphorylated and 
is located at site of membrane and microfilament interactions (Toker et al. 1994). This 
could explain the requirement for intact PI 3-kinase signalling in migration and actin 
polymerisation of T lymphocytes and the inability to detect calcium mobilisation. 
Several other groups have implicated PI 3-kinase to be involved in the regulation of 
actin polymerisation and chemotaxis. For instance, FMLP stimulation of human 
neutrophil locomotion occurs with an increase in PI 3-kinase activity (Okada et al.
1994), and platelet derived growth factor mediated actin rearrangements in fibroblasts 
are sensitive to nanomolar concentrations of wortmannin (Wennstrom et al. 1994).
165
The recent work indicating the involvement of the Ras GTPases downstream of PI 3- 
kinase (see introduction) would also suggest a role for PI 3-kinase activation in 
cytoskeletal reorganisation. In fibroblasts, actin polymerisation is controlled by the Rho 
GTPase family. Filamentous cytoplasmic projections, referred to as filipodia are 
controlled by Cdc42 (Nobes & Hall 1995), Rac regulates protusions kown as 
lamellipodia which are though to have a role in cell migration and Rho controls the 
formation of stress fibres (Symons 1996). In T lymphocytes, Cdc42 has been shown 
to regulate cellular polarisation detected after antigenic stimulation (Stowers et al.
1995). Rho can be inhibited by C3 transferase which inactivates the GTPase by specific 
ADP-ribosylation, therefore this transferase could be used as a tool to identify whether 
Rho is a downstream target of RANTES induced PI 3-kinase (Fry et al. 1994). Once 
the T lymphocyte RANTES receptor has been identifed and expressed in a convenient 
cell line, overexpression of the various GTPases and mutations could be performed to 
try to identify which, if any, GTPases are involved in RANTES induced chemotactic 
effects.
RANTES induces increases in lipid kinase activity in anti-p85 subunit 
immunoprecipitates. p85 is a component of the PTK/SH2 linked isoform of PI 3-kinase 
However, the receptors that have been identifed for RANTES are G protein coupled 
(Van Riper et al. 1993; Wang et al. 1993), although none of these receptors have been 
detected on T lymphocytes. This could be explained by the existence of another 
RANTES receptor, specific for T lymphocytes, that is protein tyrosine kinase coupled. 
To support this, Bacon et al have shown that RANTES acts through two 
pharmacologically distinct signalling pathways, one linked to a PTX-sensitive G protein 
and one to PTK activation which can be inhibited by herbimycin A, a selective inhibitor
m
of Src family PTK (Bacon et al.t 1995). In addition, these pathways appear to be 
independent, because each remained unaltered when the other was fully inhibited. 
However, another possibility is that the RANTES/G protein coupled receptor may be 
activating a PTK/SH2 coupled PI 3-kinase further downstream. Anti-p85 monoclonal 
antibody can remove the activity of G protein coupled PI 3-ltinases, in human platelt 
cytosol, suggesting that this activity must, in addition, involve the PTK/SH2 isoform 
of PI 3-kinase (Downes et al. , 1994).
One area that has not been covered is how RANTES binding to its putative receptor 
could bring about these effects on PI 3-kinase. The regulation of PI 3-kinase is still 
unclear and is complex. It may involve conformational changes in the subunits, 
translocation of the enzyme from the cytosol to adjaecent to the cell membrane where 
the lipid substrates are found, or phosphorylation of the PI 3-kinase subunits. Several 
models have been proposed : e.g. i) direct interaction with protein tyrosine kinase 
receptors (e.g. PDGF receptor), stimulation of the transmembrane receptor causes 
activation of its kinase domain and autophosphorylation, enabling PI 3-kinase to bind 
via its SH2 domains and thus being directly activated, or through binding via SH3 
domains on Src kinases (Otsu et al. 1991; Pleimann et al. 1994), ii) activation via the 
G protein flgamma subunit (Stephens et al. 1994), iii) more recently, experimental 
evidence has suggested that that Ras may act upstream of PI 3-kinase. Ligand bound 
receptors promote the active GTP- bound form of Ras, by enhancing the ability of 
guanine nucleotide exchange factor to accelerate the change from GDP to GTP, then 
Ras may act as a chaperone to ensure lipids and enzyme interact in activated cells (Feig 
et al. 1994) PI 3-kinase activity has been found in association with Ras (Fry et al.
1994) but clarifying whther Ras is acting upstream or downstream of PI 3-kinase has
been very difficult. Rho may also be involved, as the p85 subunit has a rhoGAP 
domain, and Rho function has been shown to be necessary for PI 3-kinase activation.
To identify whether translocation is important in RANTES activation of PI 3-kinase, 
not only should total cellular activity of PI 3-kinase be examined but in addition, the 
cells should be fractionated. PI 3-kinase activity can then be measured in the the 
subcellular fractions. If the activity of the enzyme in the membrane fraction has 
increased and the activity in the soluble fraction decreased, then translocation is 
involved in the RANTES induced activity of PI 3-kinase (Susa et al. 1992). 
Conformational changes could be detected by examining the crystal structures of the PI 
3-kinase before and after activation by RANTES (Waksman et al. 1993)
The PTK inhibitor, herbimycin, could be used to investigate the involvement of PTK 
in RANTES activation of PI 3-kinase (Bacon et al. 1995). Anti-phosphotyrosine 
immunoprecipitates could be performed on RANTES stimulated cells and examined to 
see if they contain PI 3-kinase subunits by Western blotting with anti-p85. This would 
indicate whether RANTES is regulating PI 3-kinase activity by a tyrosine kinase 
mechanism or not (Ward et al. 1992b).
Pertussis toxin, an inhibitor of G proteins, or mastoparan (a peptide from wasp venom 
which activates certain G proteins) could be used to see if there is any involvement of 
G proteins in the RANTES induction of PI 3-kinase activity (Bacon et al. 1995; 
Weingarten et al. 1990). Immunoprecipitates with anitbodies against the Ras proteins 
could be carried out to see if PI 3-kinase activity could be co-immmunoprecipitated. 
The involvement of Rho could be clarified by using the enzyme C3 transferase which
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Fig. 4.1 Model of RANTES Signalling in T Lymphocytes
4.4 Costimulation and RANTES
Two signals are required for complete activation of T lymphocytes. Engagement of the 
TCR by Ag-MHC is not sufficient for IL-2 production and proliferation, and a second 
costimulatory signal is required (Turner et al. 1995). The major costimulatory signal 
identified is provided by the interaction of the CD28 cell surface ligand with the B7 
family on the antigen presenting cells. PI 3-kinase has been shown to be critical in 
CD28 costimulation in some T lymphocyte models (Sansom et al. 1995; Ward et al. 
1993) with abrogation of the generation of D-3 phosphoinositides resulting from CD28 
activation, preventing CD28 mediated costimulation (Ward et al. 1995). RANTES 
activates PI 3-kinase. PI 3-kinase activation has been demonstrated to be a key event 
in CD28-mediated costimulatory events. This suggested that RANTES activation of PI 
3-kinase may also provide a costimulatory signal in T lymphocyte activation. Indeed 
our results show that given specific costimulatory conditions, RANTES could modulate 
T lymphocyte proliferation.
It has previously been shown that RANTES at high concentrations of 0.1 - 10 /ig/ml 
can cause proliferation of a T helper cell line, but these concentrations do not cause 
optimal migration of T lymphocytes in vitro (Bacon et al. 1995). This study found that 
RANTES alone was ineffective in causing proliferation of primary T lymphocytes, at 
concentrations of 0.1 -100 ng/ml in vitro, and RANTES, in combination with UCHT1 
alone or CHO-B7+ alone, did not increase the levels of proliferation above those seen 
with UCHT1 alone or CHO-B7+ alone. However, when RANTES was added in 
combination with the two costimulatory factors, UCHT1 and CHO-B7+, it potentiated 
the effects seen with costimulation alone, in a concentration dependent manner, 
increasing proliferation by a factor of 2.1 +  0.3 (n = 3).
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Anti-RANTES inhibits the proliferation of the T lymphocytes seen in the presence of 
the costimulatory factors, UCHT1 and CHO-B7+. Moreover, these inhibitory effects 
seen in the presence of decreasing concentration of anti-RANTES, produce a curve that 
is the inverse to the "bell-shape-like" concentration dependent response curve 
characteristically generated in response to RANTES stimulation, in assays such as 
chemotaxis, polarisation and actin polymerisation. High concentrations of anti- 
RANTES (e.g. 5 jig/ml) and low concentrations of anti-RANTES (e.g. 0.005 /xg/ml) 
have only a fraction of the inhibitory capacity that intermediate concentrations of anti- 
RANTES such as 0.5 /*g/m1 have. Thus, this highlights the fact that high concentration 
of RANTES may induce downregulation of the RANTES effects observed, which may 
be due to increased T lymphocyte adherence or downregulation of receptors.
Anti-RANTES inhibits proliferation of costimulated T lymphocytes suggesting that 
RANTES is produced endogenously during costimulation of primary T lymphocytes. 
Large amounts of RANTES peptide (up to 25 ng/ml) are produced when primary T 
lymphocytes are costimulated with UCHT1 and CD28. This is in agreement with 
previous reports showing production of many lymphokines after T lymphocyte 
costimulation including IL-2, IL-3, IL-4, IL-5, IL-6 , TNF - a and IFN - y  (Fraser et 
al. 1993). Recently, Ortiz et al, have studied the transcription factors regulating the 
RANTES chemokine gene. AP-1, NF/cB, CD28RE, NFAT-1 and Rel-1 binding sites 
have been detected in the immediate upstream region of the RANTES gene in T cell 
lines (Ortiz et al. 1996; Nelson et al. 1993). CD28RE is a CD28 response element that 
has also shown to be located on the IL-2 promoter, and CD28 is thought to regulate IL- 
2 expression through this binding site . Therefore, CD28 could regulate the RANTES 
promoter in a similar manner. Indirect evidence also suggests that CD28 costimulation
may regulate some of the other transcription factors involved in controlling the 
RANTES promoter, including c-Rel and NFkB via plG* kinase, and AP-1 via JNK 
activation (Fraser et al. 1992; Rayter et al. 1992; Rincon et al. 1994).
Purified subsets of T lymphocytes have also been examined for RANTES peptide 
secretion and mRNA expression (Conlon et al. 1995). An antibody against the TCR, 
or phorbol myristate acetate (PMA) in combination with ionomycin, were used to 
activate human peripheral blood lymphocyte subsets. Low constitutive expression of 
RANTES was observed in all the T lymphocyte subsets, but after activation (18 hours), 
chemokine expression increased and indicated that CD8 +, CD45RO+ T lymphocytes 
were the dominant source of RANTES. CD8 + cells are considered primarily as 
cytolytic cells and have been judged to have little secretory ability. These RANTES 
results would suggest that they also have a helper function and give RANTES another 
role in T lymphocyte function.
IL-2 receptor upregulation and IL-2 production are indicators of T lymphocyte 
activation. We were unable to detect any consistent induction of IL-2 receptor 
upregulation or IL-2 production when primary T lymphocytes were stimulated with 
RANTES alone. However, RANTES did potentiate IL-2 receptor upregulation seen 
with CHO-B7+ and UCHT1 in combination with CHO-B7+. This did not correlate 
with the effects on CHO-B7+ dependent proliferation, as RANTES did not cause any 
potentiation of proliferation seen with CHO-B7+ alone. This disparity suggests that 
different RANTES signalling pathways may be involved in IL-2R upregulation and 
proliferation.
IL-2 production was not affected significantly by RANTES stimulation in combination 
with either UCHT1 alone or CHO-B7+ alone. Furthermore, RANTES in combination 
with both the costimulatory factors did not upregulate IL-2 production. Therefore, 
RANTES appears to upregulate IL-2R expression without any significant effects on IL-2 
production. CD28 costimulation upregulates IL-2R a-chain (Cerdan et ah, 1992), 15- 
chain (Cerdan et ah, 1995) and 7 -chain (personal communication with S.G. Ward). 
In this study RANTES modulates expression of the IL-2R a-chain but it could also 
regulate expression of the a- and 7 -chains. RANTES signalling pathways, however, 
do not appear to be coupled to IL-2 production.
EL-2R a-chain is expressed after mitogenic or antigen stimulation of human T 
lymphocytes (Leonard et al, 1985). Expression of the a-chain gene is regulated by 
transcriptional activation and post-transcriptionally by mRNA stabilisation (Leonard et 
ah 1985; Cerdan et ah 1992). The transcription factor, NFkappaB, has been suggested 
to play a role in the regulation of the a-chain transcription in primary T cells 
(Lowenthal et ah 1989) and experiments have been carried out to show that the nuclear 
amount of the NF-kappaB complex directly correlates with IL-2R a-chain expression 
(Pimentel-Munos et ah 1994). Tumour necrosis factor-a and/or IL-2 in T lymphocytes 
activated by anti-CD3 upregulates the amount of IL-2R a-chain mRNA and surface 
expression of the a-chain was also increased (Pimentel-Muinos et ah 1994). More 
recently, work has shown that upregulation of the IL-2R B-chain is also controlled 
through combined transcriptional and post-transcriptional mechanisms (Cerdan et ah
1995). CD2 and CD28 costimulation led to an increase in transcription rate and 
transcript stabilisation of the B-chain, detected by treating with actinomycin D.
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The pathways involved in RANTES induced potentiation of the costimulatory response 
have not been identified. The findings in this study would indicate that PI 3-kinase is 
pivotal to RANTES activation of T lymphocytes, suggesting that this pathway may be 
involved in RANTES induced proliferation. However, CD28 activation is also linked 
to PI 3-kinase activity, so why activation of this enzyme by RANTES potentiates 
costimulation is not fully understood. There are several possible explanations including 
the existence of multiple PI 3-kinase isoforms with specific substrates and effector 
molecules activated by RANTES or CD28. Alternatively, the different receptors may 
couple in different ways to the same isoform of PI 3-kinase and act additively.
A possible model to explain the findings in this study is that CD28 costimulation of T 
lymphocytes not only increases IL-2 production but also causes an increase in RANTES 
production. RANTES released from the cells, could act in an autocrine manner on 
RANTES cell surface receptors on these cells, and in a paracrine manner on other T 
lymphocytes, to amplify the costimulatory response, resulting in increased proliferation 






Fig. 4.2 Model of the Role of RANTES in Costimulation of T Lymphocytes 
Presentation of an antigen by a APC to a T lymphocyte in the presence of the 
costimulatory signal not only increases IL-2 production and leads to IL-2R upregualtion, 
but causes an increase in RANTES production. RANTES released from the cells, could 
act in an autocrine manner on RANTES cell surface receptors and amplify the 
costimulatory response, resulting in increased proliferation and IL-2 receptor 
upregulation.
4.5 Conclusions
The conclusions that can be drawn from this study are several :
a) RANTES is a potent chemoattractant of primary T lymphocytes but has no effect 
on the migration of quiescent T lymphoblasts or the Jurkat T cell line suggesting 
that these transformed cells do not bind RANTES or more likely, have 
incomplete signalling pathways.
b) RANTES induced migration is preceded by RANTES induced shape change and 
actin polymerisation of T lymphocytes. These effects appear to be brought 
about through binding of the same RANTES receptor as a similar concentration 
of RANTES causes optimal induction of migration, polarisation and actin 
polymerisation.
c) The effects of RANTES on T lymphocytes do not seem to involve the classical 
phosphoinositide pathway as no elevation of [Ca++]i was detected after addition 
of RANTES. This is also supported by the inability to detect PtdOh production 
or PI(4,5)P2 breakdown after RANTES stimulation of T lymphocytes.
d) The PI 3-kinase signalling pathway is involved in RANTES signalling in T 
lymphocytes since PI 3-kinase activity is induced after treatment with RANTES 
and wortmannin, a PI 3-kinase inhibitor, inhibits RANTES induced migration, 
shape change, actin polymerisation and increase in PI 3-kinase activity. There 
is evidence to suggest that these effects of RANTES work through two different
PI 3-kinase enzymes as the IC50 for wortmannin inhibition of RANTES induced 
migration, shape change and actin polymerisation is much lower than the IC50 
for wortmannin inhibition of RANTES induced increase in PI 3-kinase activity.
RANTES peptide is produced after costimulation of T lymphocytes. This result 
and the observation that proliferation induced by costimulation of T lymphocytes 
is partially inhibited in the presence of anti-RANTES indicates that RANTES has 
an important role in T lymphocyte proliferation. In addition the levels of 
proliferation seen after costimulation of T lymphocytes can be increased if the 
cells are costimulated in the presence of RANTES.
CHO-B7+ stimulation of T lymphocytes only very slightly causes upregulation 
of the IL-2 receptor but if this treatment if repeated in the presence of RANTES, 
the upregulation is markedly increased. The upregulation of the IL-2 receptor 
detected after costimulation of the T lymphocytes is also upregulated in the 
presence of RANTES.
In contrast, production of IL-2 by T lymphocytes after costimulation is not 
increased if the costimulation is repeated in the presence of RANTES. 
Therefore, RANTES appears to upregulate the IL-2R without any significant 
effect on IL-2 production. The disparity in potentiating effects of RANTES in
e), f), g) suggest that different RANTES signalling pathways are involved in the 
various physiological signals.
4.6 Implications
RANTES is a potent chemoattractant for T lymphocytes but the attraction of T 
lymphocytes to sites of infection is not its only role. RANTES potentiates the 
proliferation response of T lymphocytes to costimulation and so the production of 
RANTES peptide detected after costimulation of T lymphocytes will enhance the 
proliferative effects already observed. No other related C-C chemokines have been 
shown to have any effects on proliferation of T lymphocytes (Bacon et al. 1995) and 
so this gives RANTES an unique function in the C-C chemokine family.
The finding that RANTES stimulation of T lymphocytes at concentrations that induce 
optimal migration does not cause calcium mobilisation, suggests that calcium elevation 
and hence the classical phosphoinositide signalling pathway, is not linked to all C-C 
chemokine stimulation of T lymphocytes. However, the PI 3-kinase signalling pathway 
is involved in RANTES stimulation of T lymphocytes and so provides another target 
for therapeutic manipulation of the effects of chemokines.
A clearer understanding of the activation of leukocytes by RANTES and other 
chemokines may help to elucidate many complex immune responses and provide 
information about potential therapeutic treatment for diseases that RANTES is involved 
in, such as allergic inflammation and AIDS.
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